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Transfusion of blood is one of the oldest and most widely used clinical interventions. In
2020 the World Health Organisation reported that globally 118.5 million blood donations
had been collected worldwide. This blood will be used to provide life-saving transfusion
support for millions of individuals with a wide range of medical conditions.
To ensure the safety of each blood transfusion it is common policy to identify and
ensure compatibility between the ABO and RhD antigens of both donor and recipient.
Although this policy prevents the majority of adverse haemolytic transfusion reaction’s
(HTR), approximately 3% of recipients become sensitised following an immune reaction to
a non-self blood group antigen after a single transfusion episode. This proportion can rise
dramatically in patients requiring frequent transfusion support, with immunisation rates as
high as 60% being reported for some haemoglobinopathy patients.
Sensitisation to non-self red blood cell (RBC) antigens confers a lifetime risk of HTRs,
which from 2013 through 2017 were responsible for 17% (32 of 185) and 6% (7 of 110) of
transfusion-related deaths reported to the US Food and Drug Administration and Serious
Hazards of Transfusion UK, respectively. Furthermore, sensitisation can render transfusion-
dependent patients non-transfusable and cause haemolytic disease in pregnancy which is
potentially life-threatening to the fetus. A more precise blood matching policy will reduce
sensitisation rates, however, adoption of this is resisted because of perceived logistical
challenges, donor typing costs, and the lack of evidence from large scale clinical trials that
reducing sensitisation rates results in health gains.
Antibody-based haemagglutination tests are the current gold standard for RBC antigen
typing; however, reliable reagents and high-throughput techniques are not available for all
clinically relevant antigens. DNA-based tests have been used to overcome these limitations,
and a range of in-house and commercial assays have been developed for donor genotyping.
However, due to the limited number of antigens typed for and the low throughput capacity of
these assays, they have not been widely applied to blood donor typing.
Advances in the technologies used for genome-wide genotyping and sequencing have
substantially reduced the cost of generating genetic variation data at population scale. Mul-
tiple studies have demonstrated that it is possible to extract antigen typing information
from the data produced by these technologies, indicating that they could be used to deliver
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genomics-based precision transfusion medicine to the patient bedside. However, the same
studies also highlight a series of challenges that would have to be overcome before these
technologies could be safely integrated into the clinical laboratory.
In this thesis, I will present the work that has been done to overcome some of the
issues surrounding the interpretation of blood cell antigen typing from genomic data and the
development of a universal donor genotyping platform which can be used by blood supply
organisations worldwide to implement of a policy of precision transfusion medicine.
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Chapter 1
Introduction
1.1 A brief history of blood transfusion
In 1825 James Blundell, an obstetrician at Guys and St. Thomas’ Hospital in London, infused
a woman suffering severe postpartum haemorrhage with four ounces of her husbands blood.
Amazingly she survived, and thus the first successful human-to-human blood transfusion
was documented. In the following years, Blundell repeated the procedure with varying
degrees of success leading him to acknowledge that there were serious risks associated with
"the operation", and that with the current level of knowledge it seemed right to "confine
transfusion to the first class of cases only, namely those in which there seems to be no hope
for the patient unless blood can be thrown into the veins”.[1] Due to unpredictable and unsafe
results, blood transfusions were generally avoided for the remainder of the 19th century.
Things began to change in 1901 when Karl Landsteiner discovered the ABO blood
group by mixing sera and red cells from 22 different individuals.[2] He observed that some
combinations would agglutinate, and deduced a pattern which allowed his subjects to be
divided into three groups; A, B and C (later 0). A year later his students performed a follow-
up study with 155 individuals, confirming the earlier findings and also identifying four
individuals who did not fall into any of the three groups, later these people were classified as
group AB. Landsteiner had identified that most people had "naturally occurring" antibodies
in their sera which could react to antigens present on the red cells of others, causing the
donor red cells to be broken down once transfused (haemolysis).
Although Landsteiner’s discovery explains why early transfusions had been so unpre-
dictable, it was not until 1907 that an American surgeon, Reuben Ottenberg, suggested that it
might be a good idea if both donor and recipient were ABO grouped before transfusion and
their blood mixed in the laboratory (cross-matched) to ensure compatibility. Pre-transfusion
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blood group testing dramatically increased the safety of human blood transfusions and as a
result, they became steadily more popular in clinical practice.
Despite matching for the ABO blood group system, adverse reactions following blood
transfusions were still reported for some patients and several individuals continued the
search for undiscovered blood group antigens using antibody-mediated agglutination. In
1927 Landsteiner and Levine discovered the M, N and P blood group antigens in rabbits
immunised with human red cells, and in 1939 Landsteiner and Wiener identified the Rhesus
antigen (now known as D) by injecting rhesus monkey red cells into rabbits and guinea
pigs.[3, 4]
The early search for human blood groups was impeded by the fact that only antibodies of
the IgM class which directly agglutinated red cells could be studied. The barrier to discovery
was overcome in 1945 by Coombs, Mourant, and Race who developed the indirect anti-
globulin test.[5] This new method, based on the property of anti-human antibodies to bind
human antibodies, enabled the detection of antibodies of the IgG class which do not directly
agglutinate red cells. This important development led to an explosion in the discovery rate of
new blood groups and has underpinned the field of transfusion medicine to date.
1.2 Blood group antigens 3
1.2 Blood group antigens
The term ’blood group’ usually refers to blood cell surface antigens, predominantly those on
the surface of red blood cells (RBC). Antigens can be proteins, glycoproteins or glycolipids,
which form part of the red cell membrane (see Fig. 1.1). They have numerous functions such
as; membrane transporters (Diego, Kidd), receptor and adhesion molecules (Duffy, Lutheran),
complement regulatory glycoproteins (Cromer, Knops), enzymes (Yt, Kell, Dombrock),














































Fig. 1.1 Cartoon showing the different types of red cell antigens. The erythrocyte membrane
is represented in the centre of the image, above this represents the outside of the cell and
below inside. Figure modified from [6].
It is the presence and absence due to inherited variation of red cell surface antigens that
defines the blood group of an individual. Antigens are defined by antibodies that occur either
‘naturally’ due to encountering antigens ubiquitous in the environment (e.g. anti-A which
is specific to the A antigen) or are formed as a result of active immunisation to non-self
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RBC antigens following exposure to human RBCs from another individual (e.g. formation
of anti-D, which is specific to the D antigen, if a D-negative patient is transfused with blood
from a D-positive donor).
Blood group systems are officially defined as ’systems of one or more antigens governed
by a single gene or complex of two or more closely linked homologous genes with virtually
no recombination between them’. Each system is genetically discrete from every other blood
group system. In order for a blood group system to be established the underlying gene must
be identified and sequenced. The International Society of Blood Transfusion (ISBT) Working
Party for Red Cell Immunogenetics and Blood Group Terminology (ISBT WP) maintains an
official record of all currently recognised blood group systems. There are currently 36 blood
group systems containing 326 red cell antigens.[7]
The ISBT also maintain three categories for antigens that have not yet been linked to
blood group systems. Collections were designed to group antigens that are biochemically,
genetically or serologically similar where the genetic basis has not yet been discovered; there
are currently 5 collections containing 14 antigens. There are also two antigen series; the 700
series contains antigens that do not fit into any system or collection which have an incidence
of <1% across all human ethnic populations, and the 901 series contains antigens that have a
frequency >99% across populations of different ethnic ancestry. There are currently 16 and 4
antigens in the 700 and 901 series, respectively.[7]
The work in this thesis will predominately focus on the RBC antigens in blood group
systems.
1.3 Pre-transfusion testing and donor screening
To ensure the safety of a blood transfusion it is important to accurately identify the blood
groups of both recipient and donor. Not all blood group antigens stimulate clinically signifi-
cant antibodies.(see Fig. 1.2).
For general purposes there are three requirements for the prevention of alloimmunisation
following RBC transfusion; 1) The RBCs of the donor must be ABO compatible, 2) RBCs
from a D-positive donor should ideally not be given to individuals who are D-negative and
must not be given to D-negative women of child-bearing age, and 3) the RBCs should be
obtained from a donor who lacks the antigens that the recipient has been previously sensitised
to. Patients who are transfusion dependant, such as those with Haemoglobinopathies, require
more careful blood matching as the likeliness of an alloimmunisation event is increased
because of the repeated transfusions.
1.3 Pre-transfusion testing and donor screening 5
Fig. 1.2 Clinical significance of each blood group. The number of antigens in each system
is shown. Bars are coloured to indicate the incidence of haemolytic transfusion reactions
and haemolytic disease of the foetus and newborn for each system. Blood group systems
with antigens that frequently stimulate clinically important alloantibodies are shown in red,
those which occasionally stimulate clinically important alloantibodies are shown in orange,
those which rarely stimulate clinically important alloantibodies are shown in green. Figure
modified from [6].
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Typing by antibody-mediated haemagglutination is the current gold standard approach for
donors and patients; this method is also referred to as ’typing by serology’. These tests rely
on antibody-mediated agglutination of RBCs and have been the foundation of pre-transfusion
testing and donor typing since the discovery of human blood groups in 1901. Early testing
was limited to antigens for which the cognate antibodies were of the IgM type and could
directly agglutinate RBCs. In 1945 the field was revolutionised following the discovery that
anti-human antibodies could be used to agglutinate RBCs which were sensitised with IgG
antibodies against a RBC antigen and thereby cause indirect agglutination. The indirect
antiglobulin test (also known as the Coombs test) allowed a large number of RBC antigens to
be identified and new blood group systems to be defined.[5]
Early antibody typing reagents were of polyclonal origin, either obtained from patients
sensitised by transfusion or during pregnancy. Such human antisera contain many different
antibody specificities and such ’contaminating antibodies’ were frequently the cause of
erroneous false-positive antigen typing results. Furthermore, there was no batch-to-batch
consistency for this generation of polyclonal typing reagents. In addition, antisera frequently
contained anti-HLA antibodies and the RBCs of a fraction of donors do express HLA class I
antigens, particularly from the HLA-B locus.
In 1975 a second revolution hit the field, and the world, when Köhler and Milstein
published a method for obtaining murine monoclonal antibodies by fusing lymphocytes from
the spleens of specifically immunised mice with mouse myeloma cells.[8] The method was
used to produce murine monoclonal typing reagents that allowed specific typing for a wide
range of blood group antigens (anti-A, -B, -P, P1, -Pk, -I, -Lea, -Leb, -M, N, -k). The first
human monoclonal antibodies with blood group specificity were produced in 1980 by the
transformation of lymphocytes from D-immunised donors with Epstein Barr Virus (EBV)
into antigen secreting lymphoblastoid cells.[9, 10] EBV-transformed cell lines proved too
unstable for reliable industrial production of monoclonal anti-D, and the method was replaced
by a technique in which human lymphocytes are fused with Murine myelomas to produce
stable heteromyeloma cell lines.[11, 12] The latter method was used to produce many of the
diagnostic monoclonal typing antibodies still in use today (anti-D, -C, -c, -E, -e, G, K, Jka,
Jkb, H, -Le(a, -Leb, -IgG, -C3d).
Currently, automated antibody typing systems such as the Olympus PK7200 are used to
type the RBC antigens of donors in major systems such as ABO and RH. Typing for less
common and rare antigens is done via manual 96-well plate based antibody haemagglutination
and antisera titration methods. Hospital blood banks predominantly use medium-throughput
methods for ABO and D typing of patients such as Gel-cards.
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There are several situations where serological typing of RBC antigens is impractical,
unreliable or unavailable. As discussed, serological typing relies either on the availability
of typing antibodies or human antisera. For some RBC antigens, these are simply not
available or are not reliable, for example, there is no existing antibody for accurate Dombrock
antigen typing. Finally, following transfusion mixed field haemagglutination may prevent
accurate typing. Patients with warm-type RBC autoantibodies and a positive direct anti-
globulin test cannot be reliably typed. Likewise, the administration of therapeutic monoclonal
antibodies for the treatment of myeloma renders the indirect antiglobulin test unsuitable for
pre-transfusion antibody detection.
It is for these reasons that immunohematologists have turned to the knowledge of blood
group genetics to develop DNA based antigen genotyping tests.
1.4 The molecular basis of blood group antigens
Blood group antigen systems can be divided into two categories; 1) those where the primary
product of the system gene(s) are glycosyltransferase enzymes which have a role in attach-
ment of carbohydrates to existing RBC membrane structures (e.g. ABO) and 2) those where
the antigen is the primary protein product of the system gene(s) (e.g. Kel).[6] Expression of
blood group antigens can be controlled by single nucleotide polymorphisms (SNPs), small
insertions or deletions (indels), larger-scale structural variations and genetic rearrangements
(SVs), or combinations of these.[13, 14] It is easiest to understand the concepts of antigen
expression with examples.
1.4.1 The ABO blood group system
The A and B antigens of the ABO system are carbohydrate determinants. Their expres-
sion is controlled by a combination of SNPs in the ABO gene of an individual which
encodes a glycosyltransferase enzyme. They are distinguished from one another by an
immunodominant terminal monosaccharide attached to a carbohydrate carrier structure,
with N-acetylegalactosamine (GalNAc) or galactose (Gal) being added in group A and B,
respectively (see Fig. 1.3).[15, 16]
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Fig. 1.3 Biosynthesis of A and B antigens from H antigen (Type 2 H shown).
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A combination of SNPs at the ABO locus controls an individual’s capacity to produce
GalNAc-transferase or Gal-transferase which catalyse the biosynthesis of the A or B antigen,
respectively. The A and B alleles of the ABO gene differ by 7 nucleotides, four of which
are non-synonymous (ns) ones resulting in amino acid sequence changes that alter enzyme
structure and function (see Fig. 1.4). The O phenotype, a lack of either A or B antigen, is
due to a non-functional ABO gene. The most common O allele is identical to the A1 allele
but contains a deletion resulting in a frameshift and premature stop codon, producing a
non-functional protein that lacks its catalytic domain. It is important to note that there are
important differences in ABO allele frequencies between individuals of different ethnicities.
A1 (A101) is most common in Caucasians (90%), A1 (A102) is most common in Asians
(85%), the two alleles differ by one nsSNP, resulting in the amino acid polymorphism
p.(Pro156Leu). For blood group O phenotypes, O1 (O01) (LRG_792:c.261delG) is the most
common genotype in Caucasian populations while O2 (O03) (c.802GG>AG) is common in
individuals of African ancestry.[17]
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Fig. 1.4 Molecular configuration of 6 common ABO gene alleles. Black line represents cDNA
sequence; coloured block represents protein product. cDNA changes are above each image;
amino acid changes are below. Amino acid changes affecting the catalytic domain are shown
in red. Changes are relative to A1 (A101). Figure modified from [6].
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1.4.2 The Kell blood group system
In contrast to ABO the Kell blood group antigens are protein determinants. The Kell glyco-
protein is the direct product of the KEL gene and carries 34 antigens.[18] In comparison to
the ABO blood group system, the molecular genetics of the Kell system is relatively simple.
Expression of the antithetical antigens, K (KEL*01.01) and k (KEL*02), is controlled by a
single nsSNP (LRG_799:c.578>T). Kpa and Kpb are two other antithetical Kell system anti-
gens which are also controlled by another SNP (LRG_799:c.841C>T). Other Kell phenotypes
with more complex molecular genetics do exist, for example, there are Kellnull phenotypes
resulting from a lack of the entire Kell protein caused by splice site disruption or multiple
SNPs leading to a premature stop codon. Individuals with this genetic configuration and
phenotype are extremely rare.[19, 20]
1.5 Donor Genotyping
The ISBT WP maintain reference tables for each blood group system which link known
combinations of SNPs, indels and SVs to blood group phenotypes. By using the information
in these tables we can create algorithms that allow inference of antigen type given some DNA
typing information for an individual (see Fig. 1.1).























Fig. 1.5 Cartoon showing a simplified ABO genotyping algorithm. This could be applied to
the variants shown in Fig. 1.4. Figure modified from [21]
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A plethora of donor genotyping tests for typing RBC antigens and Human Platelet Anti-
gens (HPA) antigens has been developed which use a wide range of technologies.[22] The
earliest tests used Restriction Fragment Length Polymorphism (RFLP) in which restriction
digest of a PCR product is changed by the variant of interest or PCR with sequence-specific
primers (PCR-SSP) in which a PCR product is generated only when a specific sequencing
is present.[23–25] Although analysis of these tests is cumbersome due to agarose gel elec-
trophoresis being difficult to automate, many laboratory developed RFLP or PCR-SSP tests
are still widely used by blood services today when more advanced assays are either not
available or cost prohibitive.[26–28]
The next generation of antigen genotyping assays used a variety of techniques to automate
analysis of PCR products. TaqMan real time based fluorescent detection of PCR products
(RT-PCR) has been used for both RBC and HPA typing, with the latest market entry focusing
on ABO antigen genotyping.[29, 30] The most important ongoing use of RT-PCR has been
non-invasive foetal RHD genotyping.[31] LightCyler PCR product melt point analysis, in
which the sequence specific melt-curve of a PCR product is used to detect presence/absence
of SNPs, has been used to genotype donors for antigens in the Kell, Kidd, Duffy, MNS,
Colton, Dombrock, and Lutheran systems but the technique is susceptible to errors due to
unknown sequence variation.[32] Commercial and in-house developed MALDI-TOF assays
have been used for typing HPA and Kell antigen typing and are cost effective to run, but they
are limited in the number of DNA polymorphisms that can be detected in a single run.[33, 34]
The main commercial assays on the market today are the HEA BeadChip and the Blood-
Chip assay. The HEA BeadChip is based on a short extension reaction of oligonucleotide
probes bound to colour-encoded beads using a PCR product as template. The test can type
antigens in the RHCE, KEL, FY, DO, LW, CO, SC, LU, DI, JK, MNS blood group systems,
but lacks the ability to type the ABO and RHD system antigens.[35] The BloodChip assay
is based on allele- and spatial- specific hybridisation of PCR products to complementary
oligonucleotides affixed to glass arrays and can be used for clinical typing of 13 RBC antigens
(JK, FY, KEL, RH, MNS and DO).[36, 37] Studies using these assays in combination with
antibody-based typing have shown that the typing data produced can dramatically increase
the availability of antigen negative blood, with one group reporting that they were able to
provide blood for 99.8% (5661/5672) of complex blood requests using just 43,066 geno-
typed donors.[38] In cases where PCR based assays cannot explain a serology phenotype or
alloantibody formation, then Sanger sequencing is performed, generally focusing on single
exons.
Although many of the assays discussed have gone through regulatory approval for
labelling of blood products they have not been widely adopted. This is because the current
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commercially available RBC antigen genotyping assays can only detect a limited number
of variants and for general typing of the most important systems such as ABO and RH are
far more expensive than serological methods. Furthermore, the molecular genetics of some
blood group antigens, such as N of the MNS system, is complex and poorly understood and it
is thought that serological methods may be more accurate than their DNA based counterparts.
1.6 Population Scale Genotyping
The first draft of the human genome was released in the year 2000.[39] Since then, the
reference sequence of the genome (reference genome) has undergone continued re-versioning
with each iteration improving the accuracy of gene structures and overall sequence. By
comparing the genome sequence of an individual to the reference genome, millions of
genetic variants can be identified where the two sequences differ. Through international
collaborations the minor allele frequencies (MAFs) of these variants have been defined for
several of the ancestral populations at a genome-wide level.
Initially this was done at limited scale by the International HapMap project project in
which the genomes of 1,397 individuals from several ethnic groups were genotyped using
DNA microarrays.[40] The aim of the study was to identify loci in the genome for assessing
risk of common diseases and variants which control quantitative traits of biomedical interest
such as height, weight, and blood cell metrics.
In 2006 the Wellcome Trust Case Control Consortium (WTCCC) conducted the first
genome-wide association study (GWAS) in which donor samples were used. In this study
DNA samples from 2,000 NHS patients with seven common diseases and 3,000 common con-
trols (1,500 were UK blood donors) were genotyped on the Affymetrix GeneChip Mapping
Array. These first-generation genome-wide arrays contained probes for typing 500,000 DNA
variants and captured about 60% of the known common sequence variation in the genome.
The WTCCC study discovered 24 genetically independent loci associated with disease risk
thus validating that GWAS could be used as a hypothesis-free method to identify risk loci for
human diseases.[41]
The success of this pioneering study sparked a wave of successively larger GWAS meta-
analyses in which the DNA of over 0.5M individuals has been typed using genome-wide
array technology. Thousands of risk loci have been identified for the majority of common
diseases and for biomedically relevant traits, such as the parameters which are measured by
the routine full blood count analysis.[42–47] The most recent and more powerful GWAS
use data produced by the UK Biobank (UKBB) study where genotype and phenotype was
collected on a cohort of 0.5 million individuals in a consistent manner, thereby reducing
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the ’noise’ in association signals produced by the GWAS techniques applied between 2010
and 2018.[48, 49]. UKBB participants have been typed on a more advanced version of
the genome-wide Affymetrix array, named the Axiom UK BioBank array, which contains
probes for approximately 800,000 DNA variants. Using the genotyping results from this
array and by applying imputation, the minor allele frequency (MAF) for approximately 80
million non-typed DNA variants can be accurately estimated through the principle of linkage
disequilibrium (LD) down to a MAF of 0.001.
Several GWAS studies have specifically recruited and genotyped NHS Blood and Trans-
plant (NHSBT) blood donors, using the genetic data produced to inform a future strategy,
and to personalise the donation interval.[50, 51] 50,000 of the NHSBT donors enrolled in
the INTERVAL randomised controlled trial were genotyped using the UKBB array and
approximately 15,000 of these participants have also joined the national NIHR BioResource
allowing their genotypes and associated metadata to be returned to NHSBT.
In 2008 the field of genomics was further transformed following a study that used short-
read next-generation sequencing (NGS) to determine the genome sequence of a male Yoruba
from Ibadan, Nigeria.[52] Illumina commercialised the NGS technology used and a year
later the 1000 Genomes Project (1KGP) showed the feasibility of applying whole-genome
sequencing (WGS) to a large number of samples.[53]
Today, sequencing data obtained by whole exome sequencing (WES) or WGS on almost
0.5 millions of individuals has been made publicly available by projects such as the African
Genome Variation Project (UK - 1,000 genomes), the UK 10,000 project (6,000 by WES,
4,000 by WGS), gnomAD (global - v3 71,702 aggregated genomes), the NIHR BioResource
Rare Disease project (UK - 13,072 by WGS), 100KGP (UK - 100,000 by WGS) and the
TopMED (USA - 62,784 by WGS).[54–59, 58, 60] This data is easily accessed, and contains
valuable information that relates to antigen expression (see Fig. 1.6).
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Fig. 1.6 Coding variants in the 44 RBC antigen encoding genes (2020 ISBT tables) observed
in the 71,702 whole genomes of the gnomAD v3 dataset. Variants are binned by frequency
with the proportion of SNPs and indels coloured in blue and red, respectively.
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These initiatives, alongside execution of even larger scale future population genotyping
projects like the Million Veterans Project (USA - 1M array genotypes), the Taiwan Precision
Medicine Initiative (Taiwan - 20M array genotypes), GenomeAsia100K Consortium (Asia
- 100,000 genomes), the FinnGen cohort (Finland - 500,000 array genotypes), All of Us
Research Program (USA - 1M genomes) and the Early Disease Detection Research Project
UK (UK - 5M array genotypes), means that by 2025 genomic data will be available for
millions of individuals worldwide from a wide range of ethnicities. Furthermore, the DNA
extraction, sequencing, and reporting of variants from projects such as the 100KGP have been
performed to clinical standards, with sequencing done at an average of 30x read depth and
>98.7% of the genome covered at greater than >15x depth. This level of coverage means the
sequencing data can be used for diagnostic purposes as demonstrated by the 100KGP pilot
study, the results of which led the NHS Executive to secure Illumina WGS capacity for 0.5
M DNA samples for the 2020-2023 period.[60] This means WGS will become the standard
test in the UK for diagnosis of rare genetic diseases and identification of driver mutations for
selection of precision treatment regimens in cancer patients. It is likely that health services
in other countries will also begin implementing the technology over the coming decade.
Use of the technological advancements and vast data produced by the genomics commu-
nity has been extremely limited within the transfusion medicine community. The first study
to apply NGS for blood group antigen typing focused on the RHD locus and showed that
the technology was superior for detecting variation in these complex loci.[61] Researchers
then highlighted the utility of NGS genotyping for the management of transfusion-dependent
patients. A study of 35 patients with sickle cell disease reported that 62% of unexplained
alloimmunisation events could be resolved by NGS sequencing of RHD and RHCE genes,
finding that current serological methods were not accurate in identifying variant D, C/c and
E/e antigens.[62] WES has also been applied for the detection of variant RH antigens and
inference of alloimmunisation risk in children with sickle cell anaemia.[63] The earliest
attempts at automated interpretation of blood types from genomic data showed promising
results, with the BOOGIE study reporting 94% antigen typing accuracy using WGS data.
However, the software was never made publicly available for cross-validation limiting further
development.[64] In 2016 Lane and colleagues explored the possibility of using NGS in a
transfusion medicine setting by performing WGS on a single individual and using the data to
infer accurate antigen types.[65] Another study focused on antigen gene sequence variation




Even though many donor genotyping assays exist and there is evidence to suggest that
their use can improve patient care and simplify the provision of blood, they have not been
widely adopted by blood supply organisations. This is largely due to the limited number of
antigens typed for by each assay, their cost and the lack of automated analysis software for
the interpretation of results.
This means that despite the advancements made since the early days of antibody-based
typing, 85% of donors in England have no typing data for RBC antigens encoded by common
alleles (other than ABO and RH) and 94% of English donors have no typing data for rare
antigens (information from look-up in NHSBT’s PULSE database - 2019).
The results of recent studies are clear; the introduction of genomics technologies into
transfusion medicine will enable us to better classify and type blood donors and patients
thereby greatly simplifying the challenges of providing better-matched blood to patients
requiring regular transfusion.
The purpose of this study is to assess the feasibility of determining human blood groups
using the high throughput molecular techniques developed for population-scale genotyping
initiatives, namely genotyping arrays and NGS. The ultimate aim is to use the vast amount of
genomic data that is now available to guide the development of an affordable and automated
donor genotyping test, validated for typing all transfusion and transplant relevant antigens
which can be used by blood supply organisations to deliver genomics-based precision





This study involved several complex and interrelated components (Figure 1). We have written
this thesis in such a way that each results chapter will have an introductory section to frame
the work it describes.
Chapter 3 details the process of using RNA sequencing data from the BLUEPRINT study
to select and curate fixed reference sequences for each of the RBC antigen encoding genes.
Following this, we analyse whole genome sequencing data from the MedSeq, INTERVAL
and, NIHR BioResource Rare Disease studies to show the benefits of computationally
mapping the knowledge of genetic antigen expression to the human reference genome.
Chapter 4 details the development and validation of an array-based donor genotyping
assay capable of typing all RBC, HPA, and HLA antigens. First, we used the Axiom UK
Biobank version 1 array (UKBBv1 array) genotyping data from donors enrolled in the
INTERVAL study to assess if the Axiom array technology is a suitable platform for antigen
typing. Next, we selected known blood typing variants from various reference sources and
designed the 384HT Axiom Blood Typing SNP Screen Array (384 BT array). We validated
384 BT array blood typing content using DNA samples from NHSBT blood donors enrolled
in the NIHR Bioresource. Finally, combined the novel blood typing array content with the
previous UK Biobank array content, creating the UK Biobank version 2 array (UKBBv2
array) which was then validated using DNA samples from blood donors from England and
the Netherlands.
Chapter 5 details the development and validation of an affordable targeted NGS assay
for in-depth investigation of antigen types when discordance is observed between antibody
phenotyping results and genotyping results from donor screening assays such as the UKBBv2
array.
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1) Computationally map 
     blood groups to human
     genome
2) Demonstrate the power of 
     WGS for antigen typing 
1) Develop array genotyping
     assay that can type all 
     RBC, HPA and HLA antigens
2) Validate by comparing 
     array inferred antigen
     types to clinical blood types
     from electronic donor record
      
1) Develop and validate targeted 
     NGS assay for investigating 
     genotype/phenotype 
     discordance
2) Use assay to resolve discordance
     observed in chapter 4  
Fig. 2.1 High level project overview showing the purpose of each chapter, the predominant
technology used, and the sources of samples and data used.
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2.2 An overview of Axiom array genotyping
The Thermo Fisher Scientific (TFS) Axiom genotyping platform is a ligation-based microar-
ray utilising 30-mer oligonucleotide probes which are synthesised in situ on a glass slide.
Two fluorescent colour channels and spatial position on the array slide are used to detect
genotypes. There are multiple formats of the Axiom platform. The two used in this study are
the 96-format - capable of genotyping 96 samples in parallel for 800,000 DNA variants, and
the 384-format - capable of genotyping 384 samples in parallel for 50,000 DNA variants.
The surface of the glass array slide is divided into features which are 3 µm squares.
Each feature contains millions of identical unique 30 base oligonucleotide probes that are
complementary to the genomic sequence which flanks the variant of interest (either forward
or reverse). Features are replicated multiple times on each array to improve the resolution
of specific SNPs and provide redundancy in the case of failure. A<>T and C<>G variation
must also be represented by two spatially separated features as only two dyes are used, one
for A,T and another for C,G.
In a standard genotyping run sample DNA is amplified, fragmented, and then hybridised
to the probe/array complex. A solution of detection probes, many DNA probes representing
every possible combination of 9 DNA bases labelled with a base-specific ’hapten’, is then
washed over the array and covalently bonded to the array-probe/genomic-DNA complex. A
stringent wash cycle is performed to remove unbound solution probes and genomic DNA.
Staining is then performed with fluorescently labelled antibodies, laser excitation produces a
signal, and fluorescent intensity measurements are used to infer genotype.
An overview of the Axiom genotyping process is given in Fig. 2.2.











































































Fig. 2.2 Overview of Axiom array genotyping. (a) A zoom diagram showing the construction
of an Axiom array. (b) Axiom genotyping workflow. From left to right; Genomic DNA
is amplified then fragmented, fragments are captured and labelled via hybridisation to
array probes and detection probes, ligation then covalently bonds the genomic DNA to
the array/detection probe complex, finally fluorescent staining is performed followed by
excitation and imaging. (c) Cartoon representation of the genomic DNA + array/detection
probe complex. An actual image of an array during genotyping is included for reference.
24 Materials and Methods
Each DNA sample used for array validation was genotyped on the Axiom platform at the
Applied Biosystems Microarray Research Services Laboratory, Santa Clara, CA. Genotyping
was carried out in accordance with Axiom Best Practice Workflows.[67] 750ng total DNA at
30ng/µl from each sample was used.
Genotypes were called using the AxiomGT1 algorithm included with the Applied Biosys-
tems Array Power Tools v2.10.2 software (APT).[67] Quality control metrics for each plate,
sample and probeset were calculated automatically using APT. In brief, this involves ensuring
that the fraction of ‘AT’ probesets for which fluorescence is 2 standard deviations outside GC
probeset fluorescence is within range, and genotype call rates for each sample and variant
are above 95%. Probes producing values below the recommended thresholds were not used
for analysis. For variants with more than one probeset remaining, a single best probeset was
selected using Fisher’s linear discriminant as a measure of cluster resolution.
We also visually inspected genotype call plots for all newly added antigen typing probe-
sets as per the original UKBB study methodology (see Fig. 2.3).[49] Data generated by any
poorly performing probesets identified at this stage were not used in further analysis.
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Fig. 2.3 Genotype call plots were visually inspected as part of DNA probe performance
assessment. Examples of (a) a “good quality” call plot with clear separation between
genotype clusters; (b a “requires development” call plot, three unique genotype clusters can
be observed, however, boundaries are too close; (c) a “poor quality” call plot with overlap
between genotype clusters. Colour represents genotype call: homozygous reference (purple),
heterozygous (blue), homozygous alternate (green); failed call (red).
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2.3 Next Generation Sequencing
Illumna Next Generation Sequencing (NGS) technology uses the sequencing by DNA synthe-
sis technique.[68] In brief, genomic DNA is fragmented and short oligonucleotide sequencing
adaptors are ligated onto the ends of each fragment, the DNA fragments are then loaded
into a flow cell and fixed via binding of adaptors to complementary oligonucleotides bound
to the flow cell surface, bridge amplification via PCR is then conducted to form clusters of
identical DNA strands in localised regions of the flow cell surface. A number of sequencing
cycles follow this in which fluorescently-labelled reversible terminator bound dNTPs are
added to the flow cell, DNA synthesis using the clustered DNA fragments as templates is
preformed and a single dNTP is incorporated each cycle, the reaction is stopped after a given
time and unincorporated dNTP’s are washed away, imaging is performed, and finally the
terminator/label is chemically removed from the forming DNA strand. The actual DNA
sequence for each read is then reconstructed using the images taken.
An overview of the Illumina short-read NGS process is given in Fig. 2.4.

































































Process repeated many times...
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...
Sequencing
Sequence reconstruced from images
Fig. 2.4 Overview of Illumina NGS sequencing
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Following sequencing, the millions of reads produced are computationally aligned to a
reference genome (see Fig. 2.5).
GRCh37 chr1:3,689,255-3,692,646
SMIM1
Fig. 2.5 NGS sequence alignment at the SMIM1 loci which is responsible for Vel antigen
expression. From top to bottom; A map view of the chromosome with red box indicating the
location of the viewing window. Next, a histogram showing read depth (the number of reads
aligned over a particular nucleotide position). Next, the alignment view mapped Reads are
shown as grey boxes, a point at either end indicates the orientation of the read (forward > or
reverse <). The structure of the SMIM1 gene is shown in blue at the bottom of the figure, the
thin line with arrows represents intronic sequence, thick and thin boxes represent transcribed
and un-transcribed exonic regions, respectively.
2.3 Next Generation Sequencing 29
Targeted sequencing
In chapter 5 a targeted or capture-based NGS sequencing assay was developed to resolve
discordance between clinical and array antigen typing results. The only difference between
standard NGS and capture sequencing is a hybridisation capture step between DNA fragmen-
tation and adaptor ligation. In this step target DNA is hybridised to oligonucleotides primers
or ’baits’ affixed to synthetic beads, the bait oligos are complementary to the genomic region
of interest. Following hybridisation a wash step is used to remove unbound ’off-target’ DNA,
thus enriching the sequencing library for the region of interest.
Targeted sequencing was performed as follows. Aliquots of original DNA samples were
retrieved from research biobanks and 1 µg of each sample was fragmented using Covaris
E220 (Covaris Inc., Woburn, MA) to obtain 150 bp average size fragments. Samples were
processed using the TruSeq DNA LT Prep kit (Illumina Inc., San Diego, CA). Two DNA
libraries were captured at the same time using a single reaction of the SeqCap BG capture
array (ROCHE NimbleGen, Inc. Madison, WI). Enrichment was tested by qPCR measuring
the abundance of four control target regions before and after DNA capture. The libraries
were quantified using the Library quantification method (KAPA Biosystem, Ltd, Cape Town,
South Africa) and sequenced by the CRUK Cambridge Institute Core Genomics facility in
pools of 24 samples in one Illumina HiSeq 2000 lane using 150bp paired-end sequencing.
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2.4 Bioinformatics
2.4.1 bloodTyper
All genetically inferred RBC and PLT antigen typing results presented in this work were
produced using the bloodTyper algorithm. bloodTyper utilises a curated antigen allele
database, containing all known antigen encoding variants, to infer antigen status from
genomic data. An in-depth explanation of the bloodTyper algorithm has been previously
published.[65]
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      CHR          POS       REF  ALT    GT
         1      159175353   G      A      0/1
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Rh: RHD and RHCE
Workows
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Fig. 2.6 Overview of the bloodTyper analysis pipeline.
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2.4.2 HLA impute
All genetically inferred 4-digit HLA typing results presented in this work were produced using
the HLA*IMP:02 imputation algorithm. HLA*IMP:02 uses a multi-population reference
panel to build a graphical representation of haplotype structure at the HLA locus, accounting
for genotype error and haplotypic heterogeneity. In layman’s terms, the frequency information
for all genetic variants across the HLA locus is extracted from a set of known HLA typed
haplotype reference sequenced. Then the probability of each combination of the variants is
mapped into a graph structure.
The model then computes a probabilistic HLA type for each sample, given their sequence.
An in-depth explanation of the HLA*IMP:02 algorithm has been previously published.[69]
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Fig. 2.7 Overview of the HLA*IMP:02 model. (a) A graphical representation of all haplo-
types is created for the HLA locus. Blue dots represent nodes at each graph vertex (column).
The paths between vertices represent different possible variants, the reference panel proba-
bility of a given nucleotide and the nucleotide itself is annotated on top of each path. We
show the probability of different HLA-DQRB1 genotypes in red, these are linked to each
possible path through the graph. (b) Use of the haplotype graph to impute HLA types. Se-
quence, haplotype graph path, and predicted HLA-DQRB1 type is shown for three theoretical
samples.
34 Materials and Methods
2.4.3 BWA, SAMtools, and BCFtools
BWAv 0.7.12, SAMtools v1.9, and BCFtools v1.9 were used extensively during this project
for the processing of genomic data. All three are available for download free of charge online
at https://github.com/lh3/bwa and https://github.com/samtools/.
BWA is a software tool for alignment of sequencing reads to reference genomes. Three
alignment algorithms are available. The latest, BWA-MEM, was to produce all sequencing
alignments in this study.[70]
SAMtools is a software library for processing genotyping and sequencing data. It is used
to convert between alignment formats, sort and merge alignments, remove PCR duplicates,
and generate per-position information in the pileup format. [70]
BCFtools is an extension to the original SAMtools software package and sits within
the HTSlib environment. It is used for the manipulation of VCF files including; format
conversion, querying, genotype annotation, and sequence reconstruction.[71]
2.4.4 Genome Analysis Toolkit, Manta and Canvas
Three variant callers were used in this study to detect genetic variants from NGS data. The
Genome Analysis Toolkit (GATK) v3.1 was used for calling SNPs and indels.[72] Manta v1.6
and Canvas v1.3 were used to call structural variants (SVs).[73, 74] All three are available
for download free of charge.
GATK is a standard software package for identifying genetic variants from NGS sequenc-
ing data. In addition to several variant callers, GATK also includes quality control utilities
such as Picard for de-duplication of sequencing reads. GATK does not currently support
calling of structural variants.
Manta is an SV caller that uses paired and split-read evidence (paired reads for which
opposite ends align to different parts of the genome) to identify SV breakpoints. Canvas is
also an SV caller, however uses differences in read depths for the detection of SV’s. Calling
of structural variants has a higher error rate than other types of variant, in this study we
therefore cross-validate SV calls by analysing only those reported by both tools.
2.4.5 Axiom Analysis Suite
Axiom Analysis Suite, created initially by Affymetrix and now published by Thermo Fisher
Scientific is a set of freely available tools for analysing Axiom genotyping data.[75] In this
study it was used for genotyping calling and genotype quality control. Axiom Analysis Suite
is available on request from Thermo Fisher Scientific.
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2.5 Summary of external data sources
Samples and data from many different previously published studies have been used through-
out this thesis. Rather than copy out the methods of these studies we have made reference to
the publications where detailed study methodologies can be found. For ease of access, we
have also summarised this information in the below table.
Table 2.1 Data sources
Study Data Type Participant Number Participant summary Reference














INTERVAL Array and WGS 45,263 NHSBT blood donors [50]












BLUEPRINT RNAseq 90 NHSBT blood donors [80]
2.6 Blood Donor DNA samples
We made use of 11,923 DNA samples from English and Dutch blood donors in this study.
The samples and data from all participants were obtained after informed consent, see specific
panel descriptions for more detail.
2.6.1 INTERVAL panel (n=1,257)
The INTERVAL randomised control trial used data from 45,263 English donors to find the
optimum interval for which it is safe for different donors to give blood (Interval: study of
optimum frequency of blood donations in England, Research Ethics Committee reference:
11/EE/0538).[81, 50]
36 Materials and Methods
WGS data for the 200 samples used in chapter 3 was generated using 15x Illumina
short read sequencing. Array genotyping data for the 1,057 samples used in chapter 4 was
generated using the UKBBv1 array and NHSBT clinical antigen typing data was available
on request to the study organisers.
2.6.2 NIHR BioResource panel (n=507)
The NIHR BioResource is a panel of over 150,000 volunteers (NIHR BioResource – Research
Tissue Bank, Research Ethics Committee reference: 17/EE/0025), with and without health
problems. Data is made available to enable studies on the association between phenotype and
genotype. Approximately 10,000 members of the NIHR BioResource were NHSBT blood
donors and clinical antigen typing data was retrieved from NHSBT’s electronic donor record.
2.6.3 COMPARE and DIS3 panel (n=7,477)
Trial set: COMPARE study panel (n=4,795). The COMPARE study enrolled 29,066 English
blood donors between February 2016 and March 2017 (Comparison of NHSBT’s current
approach with three alternative strategies to assess haemoglobin levels in whole blood
donors (Research Ethics Committee reference: 11/EE/0335).1 The study aim is to find the
optimum technology for haemoglobin screening. All participants were active blood donors
and clinical antigen typing data was retrieved from NHSBT’s electronic donor record. The
4,795 participants used in this study were selected based on also being participants in the
NIHR BioResource.
Trial set: Donor InSight III panel (n=2,682). The Donor InSight-III (DIS-III) enrolled
3,046 Dutch blood donors to form a research panel to allow scientific insight into donor char-
acteristics, motivations and health (METC 2014/124, NL47865.018.14).[78] Additionally,
95 newly registered donors were enrolled between May 2017 and August 2017 using the
DIS-III study protocol. All participants were active blood donors and clinical antigen typing
data was retrieved from Sanquin databases. The 2,682 participants used in this study were
selected based on the availability of extracted DNA samples.
The COMPARE and DIS-III panels, totalling 7,477 English and Dutch blood donors,
were used for validation of the final donor typing array presented in this study, named the
Applied Biosystems UK Biobank – version 2 Axiom Array (UKBBv2 array).
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2.7 Clinical RBC and PLT antigen typing data
Antigen typing data for the 11,923 donors were generated using clinically accredited tests
as part of routine donor typing by NHSBT and Sanquin. Only antigen types that had been
verified by at least two independent measurements were used. We refer to these antigen
types as “clinical types” as they are a combination of antibody- and DNA- determined types.
Results were available for 48 RBC, 11 HPA and 6 HLA antigens (see Table. 2.2).
Clinical typing results for the ABO, D, C, c, E, e, K, k, Kpa, Jka, Jkb, Fya, Fyb, Lea, Leb,
Lua, M, N, S, and s and antigens were produced primarily using commercial high throughput
serological phenotyping systems, for example the Olympus PK7300 instrument. Clinical
types for the other RBC antigens were produced using in-house manual antibody-based
typing tests. In-house polymerase chain reaction (PCR) based techniques were used to type
antigens such as Doa, Dob, and LAN where no reliable antibody testing reagents are available.
HLA antigen typing results were produced using commercially available genotyping tests or
in-house next generation sequencing tests. HPA genotyping was performed using PCR based
tests developed in-house by NHSBT and Sanquin.
38 Materials and Methods
Table 2.2 Antigen typing data available in electronic donor record
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Reformatting of clinical HLA typing data
Clinical HLA typing data for DIS-III participants were recorded using several different
formats in the Sanquin database and required formatting before use. Where a multiple allele
code was used (e.g. 07:GS), a lookup table developed and maintained by NHSBT was used
to generate an allele string (e.g. *07:01*07:03*07:040). Where an allele name ended in G,
the result was not changed (e.g. A*01:01:01G). A “G” code indicates groups of alleles that
share the same sequence in the peptide-binding groove, many of the member alleles in each
group only differ in the third field which was not typed in this study. Where an allele had the
XX suffix (e.g. *02:XX) the result was converted into a single field result (e.g. *02). The XX
suffix indicates that the second field can be any allele within the primary group making any
second field comparison unreliable.
2.8 RBC and HPA Antigen typing concordance analysis
Antigens for which fewer than 10 comparisons between clinical and array antigen types
were possible were excluded from concordance analysis. We also excluded the Lea and Leb
antigens because anti-Le antibodies are not usually clinically significant and the ISBT table
required for variant interpretation is lacking.[7] P1 antigen typing was disabled in bloodTyper
as the molecular basis of this antigen was not defined at the time of platform design.
2.9 HLA antigen typing concordance analysis
Four-digit genotype inferred HLA types were compared to clinical HLA typing data extracted
from NHSBT and Sanquin databases using the following match algorithm:
1. Allele Match: Both results match for the first two fields (e.g. *32:01 and *32:01:01)
2. String Match: Clinical typing result is an ambiguous string of ‘potential’ alleles which
contains the genotype inferred result (e.g. *02:01 is within *02:01/*02:04/*02:07/*02:09)
3. Group Match: Both results match in the first field, but due to lack of clinical typing
data a second field comparison cannot be made (e.g. *24:02 and *24) Mismatch: Both
results are from different allele groups e.g. *25:01 and *26:01:01
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2.10 Data availability
Genotype data produced for blood donor DNA validation samples can be retrieved from
the European Genome-Phenome Archive (https://www.ebi.ac.uk/ega/home) at the EMBL
European Bioinformatics Institute (Hinxton, Cambridge, UK; EBI) using the following
study numbers: NIHR BioResource participants - EGAD00001005024; COMPARE study
participants - EGAD00001005023; DIS-III study participants - EGAD00001005026.
The genotype data for UK Biobank samples will be made available through a data-release
process that is being overseen by the UK Biobank (https://www.ukbiobank.ac.uk/).
Genotype and phenotype data from the National Institute for Health Research (NIHR)
BioResource Rare Diseases Pilot can be accessed by application to Genomics England Ltd
(https://www.genomicsengland.co.uk/about-gecip/joining-researchcommunity/).
2.11 My contribution to each chapter
The work presented in the thesis would not have been possible without the collaborative
efforts of many experts from around the world. For examination purposes, I have detailed
below my specific contributions to the work performed in each chapter.
Of the research in chapter 3, I was directly responsible for; 1) Bringing together the
members of the Blood Transfusion Genomics Consortium by enlisting each member, or-
ganising £5000 funding to enable the first BGC meeting, and playing an essential role in
designing the BGC research programme, 2) Analysis of Blueprint expression data for blood
group genes and in-depth curation of reference transcripts through bioinformatic analysis
and six months of weekly calls with members of the transcript curation the Locus Reference
Genomics team at the EMBL European Bioinformatics Institute. I was also responsible for
relaying suggested transcripts back to the relevant ISBT working party members for approval,
3) Quality control, alignment, variant calling and analysis of genotyping and blood typing
results using the whole genome sequencing results for 200 INTERVAL participants, 4) Blood
typing analysis of the entire NIHR BioResource Rare Disease cohort, including resolution of
the complex RHAGnull structural variant (SV) in one of the cases and guiding re-validation
of the SV variant calling pipeline used by the project as initially the large duplication and
other SVs such as deletion of the RHD gene were not being reliably detected, 5) phasing,
reconstruction and analysis of KEL gene haplotypes for the same cohort.
Of the research in chapter 4 I was directly responsible for; 1) Sample panel creation, 2)
Quality control of genotype and clinical antigen typing data, 3) Concordance analysis and
further development and validation of array specific RBC and PLT antigen calling algorithms,
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4) HLA type imputation, 5) Genotype array design for all cohorts except INTERVAL, 6)
All associated analysis of derived data, for example, the historical blood demand analysis.
Of the research in chapter 5 I was directly responsible for; 1) Sample panel creation, 2)
Development and quality control of the BGC capture platform, 3) Quality control and data
processing of genotype and clinical antigen typing data including relatedness analysis to
link BGC capture sequencing data to WGS data obtained from the same DNA samples, 3)
Analysis of discordant genotype and antigen typing results, 4) Analysis of derived data, for




Mapping blood group antigens to the
human genome
3.1 Abstract
In recent years genomic data for millions of individuals from around the world has been
made publicly available. More recent population-scale studies such as the 100,000 Genomes
Project (100KGP) in the UK and others have analysed DNA samples by whole genome
sequencing (WGS) in accordance with clinical standards allowing the data to be used in a
diagnostic setting. This investment in introducing WGS into clinical care provides many
opportunities to deliver genomics-based precision medicine to the patient bedside. In order
to achieve this within the field of transfusion medicine, the knowledge of the genetics which
underpins blood group antigen expression must be computationally mapped to the human
genome and international standards created for the analysis of genomic data with respect to
blood group antigens.
In this chapter, we discuss the formation and initial work of the Blood transfusion
Genomics Consortium (BGC). This collaboration has brought together experts in the fields
of transfusion medicine, immunogenetics, genomics and data science from around the world
with the common aim of addressing the challenges mentioned above so that genomics
technologies can be safely integrated into clinical transfusion practice. Through collaboration
with the EMBL European Bioinformatics Institute (EBI), the BGC members have conducted
the first extensive data-driven review of the International Society of Blood Transfusion (ISBT)
blood group gene reference transcripts and established fixed sequence records for each of
them, taking the first step towards creating international analysis standards.
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We go on to demonstrate the benefits of this work by using WGS data to; further develop
and validate analysis tools for blood cell antigen genotyping, provide clinically relevant
blood typing information for 13,037 patients and their close relatives who were recruited to
the NIHR BioResource WGS project, and fully explore the sequence variation observed for
these 13,037 individuals at the genetic locus which controls the Kell blood group system.
The description of part of the work in section 3.6.1 of this chapter is based on that given in:
W.J. Lane, C.M. Westhoff, N.S. Gleadall, et al., (2018). “Automated typing of red blood cell
and platelet antigens: a whole-genome sequencing study”. Lancet Haematology. 2018 Jun;
5(6): e241–e251.
The work underpinning resolution of the clinical case in section 3.6.2 of this chapter was
used in: E. Turro, et al., (2020). “Whole-genome sequencing of patients with rare diseases in
a national health system”. Nature. 2020 Jul;583(7814):96-102.
3.2 Introduction
While the initial focus of genomic medicine will be on rare disease and cancer patients, the
sequence data being generated provides the transfusion medicine community with unrivalled
opportunities to further characterise blood group relevant loci via; cataloguing DNA variant
level frequency data in different ancestral populations, the definition of haplotype sequences
for each antigen system, and identification of previously unobserved DNA variants which are
clinically relevant because they affect antigen expression. However, in order to analyse this
vast amount of data in a meaningful way, the decades of knowledge amassed on the genetics
of antigen expression on blood cells must be computationally mapped to the human genome.
Several research groups have begun this task and started using publicly available genome
sequencing and genome-wide array typing data. One such study has evaluated the sequence
data from the 1KGP and compared it with known variation described in the ISBT antigen
tables from the Red Cell Immunogenetics and Blood Group Terminology working party of
the (ISBT WP), dbRBC, and The Blood Group Antigen FactsBook.[66] The conclusions
drawn were that in many instances blood group gene reference sequences were inadequate
and that considerable effort must be put towards phasing sequence data before attempting to
infer the genotype status of variants and relate them to blood group alleles. Many errors of
different types were discovered in the reference sources (e.g. error in the initial publication
of an antigen or typographical errors in the WP tables). The results of this analysis reinforced
the importance of mapping and curating the knowledge of molecular antigen expression to
rigorous standards, which are internationally accepted.
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Additionally, the analysis of the 1KGP data revealed that only 19% of the 1,241 non-
synonymous (ns) single nucleotide variants (SNP) identified in loci encoding blood groups
were found in the WP allele tables. This finding highlights that, whilst blood groups have
been well characterised to date, there has been a significant underestimation of the underlying
genetic diversity at all blood group loci. The 1KGP was the first to pilot WGS at scale and
produced only a read-depth of 4x on average using first-generation Solexa (subsequently
bought by Illumina) instruments, thus the confidence of calls of variants of low MAFs in
the 1KGP dataset is limited. These issues have now been resolved with the high read depth
(>30x) achieved for the 100KGP and in this chapter, we show that the latter dataset gives a
highly reliable catalogue of sequence variation in antigen encoding loci.
In 2016 Lane and colleagues explored the possibility of using NGS in a transfusion
medicine setting.[65] They performed WGS on a single individual for which the RBC groups
had been previously established by clinically accredited methods. WGS data were compared
and aligned with known reference sequences for blood group genes, following which the
blood groups were deduced and compared with the clinically accredited results, with excellent
concordance being observed. This study highlighted a number of further challenges which
the transfusion community faces if it is to apply the new sequencing technologies effectively.
These include; lack of consensus on reference gene sequences; the fact that many antigen
reference sequences are ‘virtual’ composites that do not exist in humans, reference sequences
continue to be improved by automated and manual curation, posing a risk that ISBT tables are
outdated, ISBT allele nomenclature is restricted to variants that affect blood group phenotype,
and blood group alleles with >2 variants are often not captured in their entirety.
In this chapter, we detail the creation of the BGC and the process by which some of the
challenges mentioned above were met. In particular, we focus on the selection and curation
of accurate fixed reference transcripts which allows for stable mapping of antigen encoding
variants to the human genome. We go on to demonstrate the benefit of this mapping by using
it to extract comprehensive antigen types and blood group allele variation information from
WGS data of the NIHR BioResource WGS pilot project for the 100KGP.
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3.3 Chapter Workflow
In order to extract transfusion relevant information from the vast genome-wide typing data
that is currently being produced, we set out to further link the knowledge base of the
transfusion medicine community with the modern human reference genome (see Fig. 3.1).
Realising this task would require input from experts in multiple fields we created the BGC
with the aim to produce international standards for analysis of genotyping and sequencing
data with respect to blood group antigens.
Our initial task was to perform an extensive data-driven review of the ISBT blood
group gene reference sequences to address problems and inaccuracies identified in previous
publications and to establish fixed reference sequences for the antigen encoding genes.
Using the newly curated sequences, we then created or updated Locus Reference Genomic
(LRG) records for each gene and submitted this information to ISBT for review.[82] We also
worked within ISBT to systematically curate the blood group reference tables - amending
reference sequences where appropriate and linking all known antigen encoding variants to
their unique dbSNP identifiers.
Finally, we show the benefits of linking antigen expression data to the human genome by
analysing WGS data - First by extracting comprehensive antigen typing data from it, and
then by using it to assess genetic variation in the Kell blood group system.
















in  WGS Datasets 
Fig. 3.1 Cartoon representing the overall workflow of this chapter. From top to bottom; first,
the BGC was established to unite interested parties and define the standards which must be
met for global adoption of donor genotyping. The BGC then set out to curate the reference
sequences for each blood group encoding gene. Following reference curation, we worked
alongside ISBT to link antigen encoding variants in their allele tables to the human reference
genome. We then began to explore blood group-specific variation in WGS data.
48 Mapping blood group antigens to the human genome
3.4 The Blood transfusion Genomics Consortium
To ensure the high clinical standards required for safe transfusion practice are maintained as
genotyping technologies are integrated into routine service, it is essential that international
standards are set for management and interpretation of genotype data with respect to antigen
expression. To this end, we established the BGC which has united experts from blood supply
organisations, research institutions from around the globe and an industry partner with global
reach (see Fig. 3.2).
Fig. 3.2 Map of the world showing member organisations of the Blood transfusion Genomics
Consortium. From left to right, Thermo Fisher Scientific (Santa Clara, USA), The New York
Blood Centre (USA), The Brigham and Women’s Hospital - Harvard University (Boston,
USA), NHS Blood and Transplant, University of Oxford, University of Cambridge (UK),
The Sanquin Blood Foundation (Amsterdam, the Netherlands), Lund University (Sweden),
and Blutspende Zürich (Switzerland).
In 2016 the BGC held its first workshop meeting and several objectives were established
based on a review of recently published studies. We now present the work that has been done
toward the following selection of those objectives:
1. Review of the current references sequences used by ISBT for antigen encoding genes.
2. Establish fixed and standardised reference sequences for each of the known red blood
cell (RBC) antigen encoding genes.
3. Engage with ISBT to map variants contained in the blood group allele tables to genomic
datasets.
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3.5 Data driven review of ISBT reference transcripts
The ISBT WP has created a series of basic PDF tables which list the molecular changes in
genes that give rise to blood group antigens and altered blood group phenotypes. Within
each table a reference mRNA transcript is indicated against which the variation in each table
is measured. Multiple studies have identified inaccuracies in the reference sequences used
by ISBT, and no systematic evidence-based analysis has been performed to ensure that the
current sequences are accurate.
In order to address this, we used RNA sequencing (RNA-seq) data generated by the
BLUEPRINT Epigenomes of Blood Cells Consortium as a reference sequence curation
tool.[83, 84] In this dataset, gene transcript and isoform expressionhttps://www.overleaf.com/project/5e16fb39a8c03300016f4a58
levels have been estimated by RNA-seq in multiple cell types from 90 cord-blood and adult-
blood RNA samples.[80] We compared expression levels of each transcript in ENSEMBL90
for the 43 genes associated with blood group antigens by ISBT at the time of analysis in
2016 (an example of the expression data is given in Fig. 3.3).
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Fig. 3.3 BLUEPRINT expression data for the KEL gene. (a) The overall expression of the
KEL gene in each cell type measured. Y-axis: Expression is shown in fragments per kilobase
of transcript per million mapped reads (fpkm); dots indicate fpkm values in a single RNA
preparation. Here it can be observed that the KEL gene is most expressed in cord-blood
Erythroblasts. (b) Heatmap of average expression values for all Ensembl transcripts in all
cell types. The level of expression is indicated by colour, with blue and red indicating low
and high expression, respectively. Here it can be observed that the transcript at the top of the
heat-map, ENST00000035526, is the most expressed in cord-blood Erythroblasts suggesting
it may be the most appropriate choice for an ISBT reference transcript.
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We then compared the most expressed transcripts in BLUEPRINT to the reference
transcripts listed in ISBT tables, suggesting amendment of the ISBT transcript where
BLUEPRINT expression data provided no evidence for the presence of the original ex-
isting one (see Table. 3.1).
Table 3.1 ISBT transcripts compared with BLUEPRINT most expressed transcripts
Blood Group Gene Name ISBT reference transcript Supported by RNAseq data Suggested Transcript
ABO ABO NM_020469.2 Yes -
MNS GYPA NM_002099.5 Yes -
MNS GYPB NM_002100.5 Yes -
MNS GYPE N/A N/A NM_198682.2
Rh RHD NM_016124.4 Yes -
Rh RHCE NM_020485.4 Yes -
Lutheran BCAM NM_005581.4 Yes -
Lutheran KLF1 NM_006563.3 Yes -
KEL KEL NM_000420.2 Yes -
Lewis FUT3 NM_000149.3 Yes -
Duffy ACKR1 NM_002036.4 Yes -
P1PK A4GALT NM_017436.4 Yes -
Kidd SLC14A1 NM_015865.6 Yes -
Diego SLC4A1 NM_000342.3 Yes -
Cartwright ACHE NM_015831.2 and NM_001282449.1 Yes -
Xg CD99 NM_002414.3 Yes -
Xg XG NM_175569.2 Yes -
Scianna ERMAP NM_001017922.1 Yes -
Dombrock ART4 NM_021071.2 Yes -
Colton AQP1 NM_198098.2 Yes -
Landsteiner Wiener ICAM4 NM_001544.4 Yes NM_001039132.2 (secondary)
Chido Rodgers C4A NM_007293.2 Yes -
Chido Rodgers C4B NM_001002029.3 Yes -
H FUT1 NM_000148.3 No NM_001329877.1
Kx XK NM_021083.2 Yes -
Cromer CD55 NM_000574.3 Yes -
Knops CR1 NM_000573.3 and NM_000651.4 Yes -
Indian CD44 NM_001001391.1 Yes -
Ok BSG NM_198589.2 Yes -
Raph CD151 NM_004357.4 Yes -
John Milton Hagen SEMA7A NM_003612.3 Yes -
I GCNT2 NM_145655.3 Yes -
Globoside B3GALNT1 NM_033169.2 Yes -
Gerbich GYPC NM_002101.4 Yes -
Gill AQP3 NM_004925.4 Yes -
Rh-associated glycoprotein RHAG NM_000324.2 Yes -
Forsman GBGT1 NM_021996.5 Yes -
Junior ABCG2 NM_004827.2 Yes -
LAN ABCB6 NM_005689.2 Yes -
VEL SMIM1 NM_001163724.2 Yes -
CD59 CD59 NM_203330.2 No NM_000611.5
AUG SLC29A1 NM_001304463.1 Yes -
Through this analysis we discovered inappropriate reference transcripts had been chosen
for three blood group antigen encoding genes, GYPE, FUT1, and CD59 of the MNS, H, and
CD59 blood group systems, respectively.
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For ICAM4 (Landsteiner Wiener) evidence of a secondary transcript, NM_001039132.2,
was observed - this transcript contains a frameshift mutation changing the last 140 amino
acids (aa) of the protein and may be important to antigen expression.
Expression of CD44 (Indian) transcripts was highly tissue specific. We confirmed that the
reference transcript NM_001001391.1 was the highest expressed transcript in Erythroblasts.
For ABCB6 (Lan) reads supporting a secondary transcript, ENST00000295750, were
observed. This transcript was only present in the Ensembl database, with RefSeq only
containing a single transcript for this gene, NM_005689.2.
GCNT2 (I) and B3GALNT1 (Globoside) were not covered at sufficient read depth in the
BLUEPRINT data, further experimental work is required to assess these genes.
Through this curation analysis, we also found out that the ISBT WP reference transcript
for SLC29A1 (Augustine) does not correspond to the reference protein. NM_001304463.1 is
listed in the ISBT WP reference table with a protein length of 456 aa but the RefSeq entry
linked to the transcript is 498 aa.
Results from this analysis were then used as a base to select fixed reference transcripts for
each gene via creation of LRG records. An LRG record contains stable reference sequences
that are used for reporting variants with clinical implications - in translation, this means
that genotyping data from any technology can be mapped to a stable LRG record allowing
genetically inferred blood types to be standardised globally.
Finally LRG records, detailing changes to the ’canonical’ reference transcript, were
then submitted to the individuals responsible for curating each ISBT WP allele table for
their approval. As a result of this work 42 of the 43 blood group genes analysed now have
approved LRG records, only GYPE is waiting for analysis by LRG curators.
In 2019, following engagement with the BGC and other genomics focused groups, the
ISBT WP begun associating the antigen encoding variants to the genome by updating their
reference sequences to the RefSeq equivalents of the LRG records and also by addition
of dbSNP identifiers for each variant. With this development, the transfusion medicine
community is now positioned to begin analysing the vast amount of genomic data available
to it.
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3.6 Exploring whole-genome sequencing data
We next sought to demonstrate the value of having standardised this knoweldge by analysing
WGS data.
3.6.1 Further validation of the bloodTyper WGS algorithm
As previously mentioned, in 2016 Lane and colleagues first demonstrated that accurate and
comprehensive antigen types could be inferred from WGS data. This was done by using the
purpose built bloodTyper software to infer blood types for a single genome. In 2018 a larger
scale validation study was carried out in which bloodTyper was trialled using 30x WGS data
from 110 American blood donors enrolled in the MedSeq project and 15x WGS data from
200 English donors enrolled in the INTERVAL trial.[50, 21] An initial subset of 20 MedSeq
samples were analysed using bloodTyper and antigen typing results compared to those on
the donor records. Concordance was 99.5% with 1,194 results correct in 1,200 comparisons
across 38 RBC and 22 HPA antigens. Discordance was observed for ABO in two donors and
for the RH system in four donors, three for C and one for D.
Following analysis of each discordant result, improvements were made to the bloodTyper
analysis software and the remaining 90 MedSeq samples were analysed. Concordance
between WGS inferred results and donor record typing was 99.8% with 5,390 results correct
in 5,400 comparisons across 38 RBC and 22 HPA antigens.
Finally, bloodTyper was trialled in a blinded fashion using 15x WGS data from 200
INTERVAL participants. Concordance between WGS inferred and donor record antigen
types was 99·2%, with 3486 correct results in 3515 comparisons across 21 RBC antigens.
Analysis of discordant results revealed that the majority of errors were due to the low 15x
average coverage of the genome data for the INTERVAL participants. In most cases the
correct antigen defining nucleotides were detected but at variant positions with a coverage
< 4x, bloodTyper does not infer blood types. In particular, the low sequencing coverage of
the genomes of INTERVAL participants caused difficulties when typing for the M antigen,
with some genomes having the antigen encoding region of the GYPA gene covered with an
average coverage of 1x and even 0x read depth.
Based on these encouraging results we now consider bloodTyper validated for use on 30x
WGS data, and advise caution when genomes have been sequenced to a lesser depth.
A full description of this validation experiment, including an in-depth discussion of
discordant results, is given in: W.J. Lane, C.M. Westhoff, N.S. Gleadall, et al., (2018).
“Automated typing of red blood cell and platelet antigens: a whole-genome sequencing
study”. Lancet Haematology. 2018 Jun; 5(6): e241–e251.
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3.6.2 Antigen typing 13,037 whole genomes
Following validation of the bloodTyper WGS algorithm, we used it to infer antigen types
for the 13,037 participants enrolled in the NIHR BioResource WGS study for rare diseases
patients and their close relatives.[60] This study was one of the pilot studies for the 100KGP
and WGS was performed to clinical standard. The vast majority of samples were analysed by
WGS at 150 bp read length, but samples sequenced early in the project have 100 bp and 125
bp read length.[60] Individuals in this study, which covered 15 distinct rare diseases domains,
were recruited from 57 National Health Service (NHS) hospitals in the United Kingdom and
26 hospitals in other countries.
Demonstrating the value of typing blood groups from WGS data generated on DNA
samples obtained from patients, we identified 144 study participants with rare antigen-
negative phenotypes. If such patients would have formed alloantibodies against the cognate
antigen then it will be challenging to identify suitable donors, should they require transfusion
support in future (see Table. 3.2); 22 of these individuals have been diagnosed with a
bleeding, thrombotic or platelet disorder and the likelihood of this category of patients
requiring transfusion is increased.
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Table 3.2 Patients in the NIHR BioResource WGS project with rare antigen negative pheno-
types
System Phenotype Patients Identified
CO Co4- 4
MNS U- 1



















One patient in this cohort, a young female from Belgium with severe haemolytic anaemia,
provided a particularly interesting example of the added value WGS brings. She had been
serologically typed as Rhnull (D-, C-, c-, E-, e-) and the Rh proteins were lacking from
her RBCs. A complete absence of the protein of the RH complex is known to be causally
associated with haemolytic anaemia and this inherited condition is incredibly rare, with only
43 Rhnull individuals being reported to the ISBT WP since the discovery of the phenotype
in 1961. Investigative genotyping focussed on the coding fraction of the RHD, RHCE and
RHAG genes performed at the Institut National de Transfusion Sanguine (INTS) in Paris
failed to identify the molecular basis of her disorder. Freely translated and in short, the INTS
report states: ’Using targeted sequencing of the coding fraction and flanking sequences of the
RHD and RHCE genes no variants with possible causality were identified. This prompted the
sequencing of the coding fraction and flanking sequences of the RHAG gene which resulted
in the identification of the splice site variant LRG_822:c.157+1g>a on a single allele. Further
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sequencing is required to identify a putative other causal variant on the alternate allele of the
RHAG gene. Results of this test will follow in due course"
Mutations of the RHAG gene are known to underpin the Rhnull phenotype if present in
homozygosity or in compound heterozygosity with another nonsense RHAG variant (see
Fig. 3.4). The INTS only identified a single causal variant in RHAG.
Fig. 3.4 INTS genotyping report of Rhnull patient
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bloodTyper was used to analyse the WGS data for this patient and we confirmed the
INTS finding of the presence of the LRG_822:c.157+1g>a Rhnull variant on a single allele
of RHAG. However, inspection of the raw sequence alignment at the RHAG loci by BGC
members revealed the presence of a large SV in this individual (see Fig. 3.5). SV callers
Manta v1.6.0 and Canvas v1.40.0 were then used to characterise the variant. Both callers
identified a tandem duplication at GRCh37 chr6:49575934-49588875.
RHAG
GRCh37 chr6:49,570,890-49,606,552
Fig. 3.5 WGS sequence alignment at RHAG loci of the Rhnull patient. The gene structure of
RHAG is shown in blue at the bottom of the figure, thick and thin sections represent exons
and introns, respectively. A red box is drawn around an area of increased read depth and
improperly mapped reads indicating presence of a structural variant.
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Confirmatory Sanger sequencing was performed for both variants on parental DNA sam-
ples in order to assess the mode of inheritance. It was revealed that the LRG_822:c.157+1g>a
splice site variant was of maternal origin and the inline duplication had been inherited from
the father (see Fig. 3.6). The identification of the two variants is highly likely causally
associated with the non-functional RHAG gene in this patient. A non-functional RHAG gene
results in the RHD and RHCE proteins being unable to incorporate into the RBC membrane
causing a Rhnull phenotype. The results obtained in this patient show the power of WGS and
the genetic results can now be used for family planning purposes.










RHAG 6:49604368 C>T, Splicing 
RHAG Tandem duplication 
6:49575934-49588875  
Proband
Fig. 3.6 Pedigree of Rhnull patient with Sanger sequencing results depicted. (black box)
shows the genotype of the RHAG chr6:49604368c>t known Rhnull causing variant. (red-
dashed box) shows heterozygous presence of the RHAG tandem duplication chr6:49575934-
49588875.
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3.6.3 Variation in the Kell blood group system
We then used the high coverage WGS data from the 13,037 NIHR BioResource individuals
to assess the extent to which ISBT WP has underestimated variation in antigen encoding
genes via the adoption of a retrospective and incomplete approach to recording haplotype
data. For the purposes of this thesis we have used the Kell blood group system as an example
locus.
First, 10,1049 variants with an overall pass rate (OPR) of >0.98 were extracted from
merged variant call files (VCF) for all samples in a 2 Mb window centred around the KEL
gene (GRCh37 chr7:141638200-143659802) using bcftools v1.9. Genotypes for all variants
in each sample were then phased using Eagle v2.1.9. This was performed without a phasing
reference panel as Eagle2 will drop variants not present in the reference panel resulting
in loss of sequence information. Phasing of genotypes is an essential step when trying to
recreate haplotypes for antigen encoding genes, as the presence of nonsense (or null in blood
group terminology) variants has a pronounced effect on overall blood group phenotype (see
Fig. 3.7). Hence it is important to determine in which haplotype the nonsense variant is
localised.














































Fig. 3.7 Cartoon showing the importance of phasing when reconstructing antigen encoding
haplotypes. (Unphased) Variation detected at the KEL locus of a theoretical individual.
Coloured blocks represent ’background’ haplotype sequences with phenotype defining cDNA
changes above each block and resulting amino acid changes and its position below. Here
the individual has both a K-/k+ phenotype allele shown in Red, and a K+k- allele shown in
Yellow. A Kellnull phenotype variant has also been detected and is represented by a Black
Triangle. (Phase State 1) Here the Kellnull variant is in phase with the K+ allele, nullifying
it, and resulting in an overall K-k+ phenotype. (Phase State 2) Here the Kellnull variant is in
phase with the k+ allele, nullifying it and resulting in an overall K+k- phenotype. As can be
seen, the phase of the Kellnull allele has a pronounced effect on overall phenotype
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We then created two sets of KEL gene consensus sequences for each individual, with two
haplotype sequences in each set, by using phased variant genotype data to modify the KEL
reference sequence (LRG_799).
The first set of consensus sequences was constructed only using genotypes for known
antigen encoding variants contained in the ISBT WP Kell system table. These sequences
can be thought of as ’ISBT reference haplotypes’ and serve to capture the known antigen
encoding variation of each individual. We identified 35 unique ISBT haplotypes in the 13,037
whole genomes and bloodTyper was used to compute phenotype and ISBT allele codes for
each of them (see Fig. 3.8). Interestingly, 7 of the 35 haplotypes were novel combinations of
ISBT Kell variants that have not yet been given ISBT allele codes. One individual possessed
a potentially new Knull allele composed of a KEL*02.01 (k+) and a premature stop variant
(LRG_799:p.Arg700Ter).
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The second set of consensus sequences was constructed using genotypes from all variants
identified within the KEL gene, these are ’complete haplotypes’ reflecting all observed
variation in the gene for each individual. We identified 1,732 unique complete haplotypes in
the same 13,037 whole genomes, a nearly 50 fold increase from the number identified when
using ISBT variants alone (see Fig. 3.9). Again, bloodTyper was used to compute antigen
phenotype and ISBT allele codes for each of them; 12 of the haplotypes identified contained
a nonsense variant leading to a premature stop before the K/k antigen defining polymorphic
position (LRG_799:c.578). The Kell protein is a type II transmembrane protein and therefore
some of the shorter isoforms encoded by the 12 haplotypes containing a nonsense variant
may be expressed on the RBC membrane, however, due to the presence of these truncating
variants the K/k antigenic site will not be present. The results of this analysis show that
antigen encoding variation within the KEL system has been grossly underestimated by the
ISBT WP. Inclusion of these Kellnull alleles in the ISBT reference tables is critically important
for patient blood group genotyping.
Fig. 3.9 Phylogenetic tree showing the complete variation in the KEL gene sequences of
13,037 individuals. Each branch represents one of 1,732 unique KEL sequences identified.
The tree is rooted on the LRG_799:c.578C>T variant which defines K+k- or K-k+ phenotype
status. Clusters are annotated with K/k phenotype.
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3.7 Discussion
Over the past decade, WES and WGS sequencing data from nearly 0.5 M research participants
has been made publicly available. Based on the results of the pilot study of the 100KGP, the
NHS has taken the decision that WGS will become the standard of care for rare disease and
cancer patients. Implementation of this new approach is now rolled out via the reconfigured
7 NHS Clinical Genomics laboratories. In this chapter, we have shown that the WGS data
can be used to infer the blood cell antigen status of both donors (the INTERVAL WGS study)
and patients (the NIHR BioResource WGS study). The transfusion medicine community
must act on this information and leverage this comprehensive data to further its knowledge
of blood group genetics and to improve health outcomes for patients. In order to achieve
this two things must first happen; 1) The knowledge of blood group antigen genetics must
be carefully curated and computationally mapped to the human reference sequence, and
2) Global standards for the interpretation of genotype data with respect to antigen typing
must be established in order to ensure the safe integration of genomics technologies into the
clinical typing laboratory.
Using the RNA-seq expression data produced by the BLUEPRINT study we have de-
livered the first data-driven review of the ISBT WP blood group gene reference sequences.
In line with the results of previous studies, we found that some of the historical references
selections were inadequate. For three loci we have recommended to the ISBT WP that new
reference transcripts are adopted as no supporting data for original transcript expression
could be found in the BLUEPRINT data. Additionally, at six loci we found evidence of
moderately expressed secondary transcripts or highly tissue-specific expression of transcripts;
in these cases, our data provide the first confirmation that the ISBT transcripts are the most
appropriate and most abundantly expressed. Most importantly, this analysis allowed us to
work with the EBI to extensively curate and establish fixed LRG records for each of the
antigen encoding genes. Fixed reference sequences that do not change with genome build
updates provide a standard to which genotype information produced by any technology can
be mapped.
We communicated the results of our analysis to the ISBT WP and in turn, they have now
updated the reference tables to use the RefSeq equivalents of the LRG records defined here.
Through continued engagement with the ISBT WP we were able to use these references to
map each known antigen encoding variant to dbSNP identifiers, cementing their position
in the human reference genome. This development, in combination with the earlier work
done by Lane et al., in 2015 and Moller et al., in 2016, means the transfusion medicine
community is now in a position to explore and use the vast amount of WES, WGS and
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array genotyping data, which will become available as clinical genomics is introduced across
healthcare systems.
In the second part of this chapter, we demonstrated the value of having a carefully curated
and standardised link between antigen phenotype and genotype by using it to analyse WGS
data.
First, we used WGS data from 310 American and English blood donors to further develop
and validate the bloodTyper algorithm. Overall excellent concordance between genotype
and phenotype was observed with 10,070 concordant results in 10,115 comparisons (99.5%
concordant). The bulk of discordant results (64%, 29 of 45) in this analysis were caused
by poor coverage of antigen encoding genes in the lower 15x depth sequencing for donors
who participated in the INTERVAL trial highlighting the importance of using clinical quality
genomes (30x) for inference of antigen status from WGS data.
We then used bloodTyper to produce comprehensive antigen typing data for 13,037
rare disease patients and their close relatives enrolled in the NIHR BioResource project for
whom 30x clinical-grade WGS data was available. We identified 144 individuals with rare
antigen-negative blood group phenotypes who may be difficult to provide blood for should
they need transfusion support and shown to have formed alloantibodies. This information
is particularly relevant for 22 of these individuals who have each been diagnosed with a
bleeding, thrombotic or platelet disorder as this category of rare disease patients has a higher
likelihood of requiring transfusion. For one patient, analysis of her WGS data elucidated the
genetic cause of her haemolytic anaemia - a fine example of how WGS data provide a higher
sensitivity than targeted sequencing to detect the genetic basis of rare inherited disorders.
Finally, we used the 30x WGS data of the 13,037 patients and their close relatives to
determine the extent which variation in the blood group encoding genes has been underesti-
mated by the transfusion medicine community. Previous work has highlighted the problem,
reporting that only 19% of the variation observed within blood group genes in the HapMap
and 1KGP datasets are reflected in the ISBT blood group allele tables. By phasing variant
genotypes and reconstructing sequences that captured variation across the entire KEL gene
locus we identified 1,697 (50x) more haplotypes than when performing the same analysis
using only variants in the ISBT WP reference tables. Importantly, in the 35 ’ISBT haplotypes’
we identified, several were novel combinations of ISBT WP recognised ones, which have
not yet been given ISBT WP allele codes. This means that although the inclusion of fixed
sequences and dbSNP identifiers in the reference tables was an important step in the right
direction, the transfusion medicine community must use high coverage WGS datasets such
as those made available by the NIHR BioResource and the 100KGP to produce fully phased
haplotype references for each of the blood group systems. Such an improved catalogue of
3.7 Discussion 67
reference haplotypes would substantially increase the accuracy of genotype phasing, which is
essential when considering the effect of nonsense (null) variants on overall antigen phenotype
and that antigens within the same system are not inherited separately but travel together
on haplotypes. In the next step, the catalogue must be enriched for haplotypes present in
individuals of non-European ancestry, this will become feasible in the near future as a large
number of WGS projects have been initiated across the world, as reviewed in the introduction
to this chapter and of this thesis.
This chapter provides an example of how integrating the transfusion community knowl-
edge with a detailed understanding of genomic data can result in the development and
validation of tools such as bloodTyper. We have used the genotype-phenotype link and
WGS data to not only further our understanding of the molecular basis of antigen expression,
but also to increase the accuracy of inferring antigen types of patients and donors from
genotype data. The BGC and ISBT WP have now taken the first steps towards producing
the international standards required for analysis of genomic data with respect to blood group
antigens, setting the scene for an era of precision transfusion medicine and genomics guided




A universal donor genotyping platform
4.1 Abstract
In this chapter, we present a genotyping platform that is capable of typing almost all clinically
relevant Red Cell, Platelet and Leukocyte antigens of an individual. The platform is composed
of two pieces of technology; 1) an array-based genotyping assay that has been designed to
interrogate all known genetic variants which underpin blood type antigen expression and
2) the bloodTyper automated analysis software for the interpretation of blood groups from
genotyping data. These two components were developed in tandem using an iterative design
process. A typical development cycle involved; genotyping DNA samples from real blood
donors, interpretation of genotype data using bloodTyper, comparison of genotype inferred
and blood service determined antigen types, and finally improvements to array content or
the bloodTyper algorithm guided by concordance analysis. Following two initial rounds
of development with a small number of samples, a validation study was performed using
a larger number of samples from 7,927 European, 27 South Asian, 21 East Asian and 9
African ancestry blood donors enrolled in two national biobank studies in England and the
Netherlands.
In addition to detailing the development and validation process, we show how the
extremely dense antigen typing data produced can be used to simplify the challenges of
supplying blood at national scale for patients with antibodies against several red blood
cell antigens. This was done by extracting antibody data from NHS Blood and Transplant
patient records over a five year period and comparing the number of potentially compatible
individuals that could be found using genotyping or current donor record typing data available
for the 7,984 validation set donors. We further demonstrate the utility of the platform by
typing Human Platelet Antigens (HPA) and Human Leukocyte Antigens (HLA) and by
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querying the genotyping data produced for the presence of variants linked to donor health -
all using the same affordable test.
The description of work in this Chapter is based on that given in N. Gleadall, B. Veld-
huisen, J.Gollub, et al., (2020). “Development and validation of a universal blood donor
genotyping platform: a multinational, prospective study”. Blood Advances, 2020
4.2 Introduction
The Alliance of Blood Operators collects 31 million units of blood each year which is used
to provide life-saving support to an estimated 15 million individuals with a wide range of
medical conditions.[85] Currently, it is common practice to match red blood cells (RBC)
for only the ABO and Rh blood groups.[86] While this policy ensures transfusion safety
and prevents the majority of fatal haemolytic transfusion reactions (HTRs), sensitisation to
non-self RBC antigens remains an unavoidable consequence of this matching strategy.
Annually, an estimated 3% (0.5 million) of patients become sensitised to RBC antigens
after a single transfusion episode, with 60% of patients receiving regular transfusions becom-
ing immunised.[87–91, 63, 92] Multiple sensitisation events, or sensitisation due to absence
of high frequency antigens can render haemoglobinopathy patients un-transfusable due to
lack of available compatible donors. Sensitisation can also cause haemolytic disease in
pregnancy, which is potentially life-threatening to the foetus and newborn. Notwithstanding
these serious side effects, the introduction of a more-precise matching policy is resisted
because of perceived logistical challenges and the cost of typing thousands of blood donors
for all antigens.[93]
Antibody-based typing tests are currently the gold standard for RBC antigen typing
however, reliable reagents and high-throughput techniques are not available for all clin-
ically relevant antigens. It is for these reasons that donor typing data is so incomplete,
even for commonly typed, clinically relevant antigens such as those of the Duffy, Kidd,
MN/Ss, and Lutheran systems. DNA-based tests have been used by blood services to over-
come these limitations and a plethora of “in-house” and some commercial assays have
been developed for specifically donor genotyping.[94, 95, 36] These range from single
variant PCR based assays to typing arrays such as the BioArrayTM, HEA BeadChip TM
from Immucore which covers a wider range of different antigens. Studies using these as-
says in combination with antibody-based typing have shown that antigen-negative blood
could be supplied for 99.8% (5661/5672) complex blood requests to a US blood bank us-
ing 43,066 donors genotyped for only 16 common antigens and antibody types for rarer
phenotypes such as Vel-negative.[38] Multiple small-scale clinical studies have shown that
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the higher resolution typing data provided by genotyping assays can improve clinical care
for transfusion-dependent haemoglobinopathy patients, particularly when used to facilitate
prophylactic matching for variant RH antigens.[96, 97]
Despite the growing evidence which supports their use, antigen genotyping assays have
not been introduced into routine service by the global blood banks. The main reasons for this
lack of uptake are; the cost of current genotyping assays, the fact that no existing test can type
all clinically relevant RBC antigens, and the lack of an algorithm for automated interpretation
of results. Furthermore, existing tests do not include typing for other transfusion relevant
antigens such as HLA and HPA, which are required for supporting cancer patients refractory
for random donor platelets because of anti-HLA and/or anti-HPA antibodies.[98, 99]
In previous studies, we have demonstrated that whole-genome sequencing (WGS) (see
Chapter 3) and whole exome sequencing (WES) methodologies can be used to produce
comprehensive and accurate RBC and HPA antigen typing data.[65, 21, 100] Although
sequencing-based tests are becoming the standard of care for transfusion-dependent patients,
these assays remain too expensive for typing vast numbers of blood donors. The unbalanced
use of genotyping technologies has created a situation in which some patients have extensive
high-resolution antigen typing data that cannot be used to improve their transfusion care as
only a relatively small number of extensively typed donors are available, which can be used
for extended matching. This issue of limited availability of typing data is even more pressing
for haemoglobinopathy patients receiving regular exchange transfusion as their requirement
can be as high as 10 units of blood per procedure, on a fortnightly basis. To remedy this
situation blood services endeavour to increase enrolment of donors of African ancestry and
ideally all these donors are to be typed with a comprehensive an affordable genotyping
test. To remedy this situation and improve clinical care, an affordable and comprehensive
genotyping test is required.
A universal donor typing platform must be able to identify all clinically relevant RBC
antigens for blood transfusions and HLA and HPA for platelet transfusions. The physical
test must be combined with software for automated data interpretation and formatting so that
it is immediately usable by blood supply organisations. Importantly, the platform must be
cost-effective and scalable to millions of donors and patients. In 2016 the Blood transfusion
Genomics Consortium (BGC) was established to capitalise on array technology recently
applied in studies to genotype thousands of individuals worldwide.[47, 50, 49] In this chapter,
we describe the validation of a high-throughput genome-wide test re-purposed for extensive
blood donor antigen typing that is available at a cost of approximately £30 per sample,
inclusive of equipment, labour cost and analysis.
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4.3 Chapter workflow
Our donor genotyping platform consists of two interrelated components: a high-throughput
genotyping assay that generates DNA typing data, and automated analysis software for
antigen typing. These two components were developed in parallel, using a strategy of
iterative improvement and evaluation using DNA samples and data from currently active
blood donors. The project can be thought of as having three main stages (see Fig. 4.1).
Stage 1 - involved assessing the suitability of the Axiom platform for donor genotyping.
Here we sought to conduct a ’proof of principle’ experiment to show that an array designed
for population screening could also be used for donor typing. To do this we inferred the blood
antigen types of 1,057 donors using pre-existing genotype data and compared our results
to NHSBT donor records. The samples and data used for the analysis were from NHSBT
donors enrolled in the INTERVAL randomised controlled trial. The DNA samples from the
donors were typed with the original UK Biobank Axiom Array (UKBBv1 array), capable of
typing approximately 800,000 DNA variants for 96 individuals in a single test cycle. It is
important to note that while this version of the array contained content for typing some RBC
antigen controlling variants, it was not designed with comprehensive donor RBC antigen
typing in mind.
Stage 2 - involved re-designing the array for donor typing. Following the encouraging
results of our initial analysis (stage 1), a donor typing only array was designed based on
a smaller testing format capable of typing 50,000 DNA variants for 384 individuals in a
single test cycle. This platform was called the 384HT Axiom Blood Typing SNP Screen
Array (384 Blood Typing Array). This included novel probes for typing 1,602 antigen typing
variants which were identified via consultation with experts in immunogenetics. In order
to assess typing accuracy of the novel 384 Blood Typing Array design, we genotyped 507
donors enrolled in the NIHR BioResource, inferred blood types from the data generated, and
compared these to existing blood types in NHSBT’s electronic donor records. The main
reasons for performing this smaller-scale trial were; to identify any manufacturing errors that
might have been made in the array design and fabrication process, examine raw data from
novel probesets to assess the quality of their design, and provide validation data for checking
software accuracy and further development of the bloodTyper software. Stage 3 - involved
performing a large scale array validation experiment. Guided by the results from previous
stages, the next round of array optimisation was performed and new antigen typing content
was integrated into the original UKBBv1 array design. This new array was called the UK
Biobank version 2 Axiom Array (UKBBv2 array). We then trialled the UKBBv2 array using
DNA samples from 7,477 English and Dutch blood donors enrolled in the COMPARE and

































Fig. 4.1 Cartoon representing iterative cycles of array development and overall chapter
workflow. (Red Track)Typical array development cycle. (Grey track) Overall project work-
flow, with significant array iterations indicated. UK Biobank array, Applied Biosystems
UK Biobank Axiom Genotyping Array; NIHR BR, National Institute for Health Research
BioResource; UK Biobank v2 array; Applied Biosystems UK Biobank version 2 Axiom
Genotyping Array; BGC, Blood transfusion Genomics Consortium, DIS-III, Donor InSight
III study.
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Donor Information Study III (DIS-III) studies. Array determined blood antigen types were
then compared to those available NHSBT and Sanquin donor records.
4.4 Stage 1 - Proof of principle
Using data available from donor records, 1,057 participants from the INTERVAL study
cohort were selected on the completeness of their RBC antigen typing data. All selected
individuals were of European ancestry by genotype. We then extracted genotype data for
these individuals from the main INTERVAL UKBBv1 Axiom variant calls file using a
combination of in-house developed scripts and bcftools v1.9. As both the serology and
genotype data contained in the INTERVAL dataset has already undergone extensive quality
control prior to release, no additional control steps were performed for this analysis.
We did however randomly select 100 individuals (including the 2 HapMap control
samples: NA19315 and NA19318) from the remaining participants in the INTERVAL cohort
and analysed their Axiom genotyping data through the pipeline to evaluate file formats and
data integrity. The custom interpretive blood typing software bloodTyper utilises a curated
antigen allele database, to infer antigen status from genomic data. Originally developed to
infer RBC antigen typing from WGS data, adaptations were required to enable bloodTyper
to process array data. Several issues with file formats were identified, and the decision was
taken to reformat array files to comply with the Variant Call Format (VCF) 4.2 specification
- a standard file format for storing genotype data. Furthermore, bloodTyper is designed
to analyse genetic variation with respect to the human reference genome GRCh37/hg19,
however, while array reported variants are positionally linked to this reference genome the
reference (ref) and alternate (alt) alleles for each array variant are not. In-house software we
developed to correct this by; 1) looking up each variant position in the reference genome,
2) comparing the ref and alt values to array ref and alt values, 3) correction of genotypes
and ref/alt values in the event a swap has occurred. Following the implementation of these
changes, a final round of pipeline compatibility testing was performed by repeat analysis of
the 100 samples to verify that all previously identified compatibility issues had been fixed
and no new ones were identified.
Inspection of these initial results revealed that some probes were clearly not working as
intended. For example, all 100 individuals typed Kellnull with the specific allele detected being
KEL*01N.01 (LRG_799:c.1678C>G). This highlighted the need to introduce a list of variants
‘to be ignored’ because of the lack of a good probeset on the array for reliable genotype
detection. The Kellnull phenotype is extremely rare; the causal variant was unobserved in the
exome aggregation consortium (ExAC) database which at the time of analysis contained the
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sequence data of 125,748 individuals. The analysis was repeated after the Kellnull variant
was added to the ‘ignore list’.
Next, UKBBv1 array genotype data for each of the 1,057 selected INTERVAL samples
were analysed using the bloodTyper algorithm and a comparison between array inferred and
donor record antigen types were performed. Concordance between array inferred and donor
record antigen types was 90.0% (14,276 concordant results in 15,862 comparisons) for 21
RBC antigens (see Fig. 4.2).
Fig. 4.2 Results from initial blood typing trial of the original UK BioBank (UKBBv1) array.
Level of concordance per antigen is shown as a percentage of the total number of comparisons
which is given at the top of each bar. Concordant and discordant results are in green and red,
respectively.
For the ABO, M, N, D, C, c, Lua, k, Kpb, Fyb and Jkb antigens concordance was unac-
ceptably poor. Detailed investigation revealed that either a lack of appropriate variant typing
or poorly performing probesets were the main reason for discordances. Some exemplars
follow:
47 discordant results were observed between ABO typing results. Further analysis
revealed that 39 (82%) of these cases were serologically group B individuals being genotyped
as group AB or serologically group O individuals being genotyped as group A. These
were explained by the lack of a probeset on the UKBBv1 array which interrogates the
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LRG_792:c.802G>A variant responsible for the second most common allele (ABO*O.01.02)
underlying the O phenotype.
Concordance for RhD antigen typing was only 32.8%. On inspection of typing results, it
was revealed that all individuals had been reported as D-negative and that any concordance
between typing results had happened by chance as approximately 30% of the NHSBT donors
participating in INTERVAL are D-negative. The most common genetic cause of the D-
phenotype in European ancestry individuals is the deletion of the entire RHD gene, and
thus, the primary method of molecular D antigen typing is the detection of this deletion.
While Axiom array technology can accurately detect deletions of this size, not enough RHD
probesets were included on the UKBBv1 array and therefore accurate copy number typing of
the RHD gene cannot be performed.
Similarly, RhC/c typing accuracy was only 28%. Further investigation revealed that the
probeset interrogating the causal variant underpinning the C and c phenotype, LRG_797:c.307C>T,
was not functioning as expected. In addition to discordance in antigen typing results, the MAF
observed in this dataset for this variant did not correspond with MAFs observed in ExAC or
the 100,000 genomes project. A working probeset was available for an alternative variant,
LRG_797: c.48G>C, that is in high linkage disequilibrium (LD) with LRG_797:c.307C>T
and can therefore be used as tag-SNP for C/c typing. A ‘force-call’ list was implemented
to the analysis pipeline, allowing blood groups to be predicted from user defined variants
such as the one in high LD. Although force-calling using this variant improved results, this
approach is not ideal as LRG_797:c.48G>C does not directly encode for the amino acid
polymoprhism which underlies the C/c antigen difference. Furthermore, the LD is not equal
to 1 and the G allele is not present in all individuals with a C phenotype.
The poor typing performance of other antigens was similarly explained by the lack
of properly performing probesets or probes for a critical variant causal of the antigenic
difference was entirely lacking. All together we can conclude that because of the high error
rate between genotype inferred and clinically determined antigen types, UKBBv1 array data
cannot be used for inference of RBC antigens in the clinical laboratory.
However, for some antigens such as Kpa and Lub, 100% concordance between DNA- and
antibody-based antigen typing results were observed. This excellent concordance indicated
that, with further development, the Axiom technology could become suitable for reliable
comprehensive donor typing. Most importantly, this analysis revealed that with inspection
of results the root cause of each discordance could be understood and a strategy formed for
resolution - namely introduction of blood typing content to the array.
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4.5 Stage 2 - Designing an array for donor genotyping
Guided by the results of our proof of principle experiment, we set out to improve the design
of the UKBBv1 array with respect to donor typing by including probesets for all known
antigen encoding variants. To this end, we identified 1,602 variants for inclusion from three
sources: 1) all antigen encoding variants known to ISBT, 2) variants suggested by the BGC
panel of experts which were known to underpin blood group antigen expression but not yet
published, and 3) variants designed to type unique regions of the RHD and RHCE gene to be
used for gene copy number identification.
Probes for identified variants were then integrated into the 384 Blood Typing Array
design. We additionally included: 4,347 variants located within RBC and HPA antigen
encoding genes, 6,572 variants located in HLA encoding genes and 31,946 variants for sex
and ancestry inference from the UKBBv1 array.
After the fabrication of the new array, Thermo Fisher genotyped 314 DNA samples from
the HapMap study and ran automated probeset quality analysis as part of their routine internal
QC process for new array designs. Additionally, genotype call-plots were drawn from this
data for the 1,602 antigen typing variants and were independently inspected by three BGC
members and ranked according to performance (See Fig. 2.3 in Methods chapter). 38 variants
important to antigen typing were identified in this analysis which did not have working
probesets and subsequently excluded from further analysis (see Table. 4.1). These 38 variants
were also given a priority ranking according to the clinical importance of phenotype, and
those identified as priority 1 (highest) variants were flagged for probeset re-design in future
validation studies.
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Table 4.1 Antigen typing variants for which no working probeset could be identified
Variant Priority Gene rsID Phenotype
1 RHD rs371803235 Partial D (Type 11) or Del
1 RHD rs142037235 Dweak (Type 18)
1 RHCE rs144348222 Rh26+ LOCR- / Rh26- LOCR+
1 RHAG rs16879498 Rh null
1 RHD rs17418085 Partial D typing, multiple
1 RHD rs1053355 Partial D typing, multiple
1 RHD rs1053356 Partial D typing, multiple
1 RHD rs1053359 Partial D typing
1 RHD (null) Partial D (DWI)
1 RHD rs1132760 Partial D (DVII type 2) Tar+
1 A4GALT (null) p (P1- pk - NOR-)
1 A4GALT (null) p (P1- pk- NOR-)
1 ABCB6 rs200125320 Lan-
1 CR1 rs41274768 Kna+ / Knb+
1 SLC14A1 rs759505281 JKnull
1 SLC14A1 rs113578396 Jkaweak
1 ITGB3 rs13306487 HPA-6a+ / HPA-6b+
1 ITGA2B rs5911 HPA-3a+ / HPA-3b+
1 ART4 rs185001341 Donull
1 RHD rs150606530 DAR3.1/4/5 (DEL)
1 RHD (null) D-
1 RHD (null) D-
1 RHCE (null) C-/c+
1 ABO rs8176743 B
2 RHCE rs144163296 STEM-
2 BCAM rs28399659 LU:–13
3 RHD rs590813 Dweak (Type 66)
3 RHD (null) Dweak (Type 58)
3 RHD rs770829982 Dweak (Type 24)
3 RHD rs17421158 Dweak (Type 14)
3 ABO (null) O
3 ITGAM rs1143679 HNA-1b Neutrophil adherence receptor
3 XK (null) Kx-
3 GP1BB rs375285857 HPA-12bw- / HPA-12bw+
3 C4A rs28357076 CH+RG- / CH-RG+
3 FUT2 rs1047781 FUT2:06
3 B3GALNT1 rs2231257 GLOB+
3 SEMA7A rs56367230 JMHK+ / JMHK-
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Then 507 NIHR BioResource samples, selected by completeness of RBC antigen typing
data on NHSBT’s electronic donor records, were genotyped using the 384 Blood Typing
Array. No samples were excluded during quality control of the genotyping data. Genotypes
were analysed using the bloodTyper pipeline, then array and donor record antigen types
compared. A significant improvement in the accuracy of genotype inferred antigen types was
observed (see Fig. 4.3).
Fig. 4.3 Results from antigen typing trial of the novel 384 Blood Typing array. Level of
concordance per antigen is shown as a percentage of the total number of comparisons which
is given at the top of each bar. Concordant and discordant results are in green and red,
respectively.
ABO genotyping accuracy increased from 95.4% in the previous experiment to 99.5%.
This was due to the inclusion of important ABO typing variants such as the already mentioned
LRG_792:c.802G>A (ABO*O.01.02) variant which encodes a group O phenotype. Two
discordant results were observed; one serology group O to genotype group B and the other
serology group O to genotype group A. Inspection of genotype and call-plots for these cases
did not reveal any reason for discordance. From this, we concluded that it is likely that
genetic variants not previously linked to the group O phenotype are responsible for the
discordances. Sequencing the ABO locus of these individuals would be the logical next
step of investigation for these two cases, however, no futher DNA or blood samples were
available.
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D genotyping accuracy increased dramatically from 32.8% to 99.8% due to accurate
detection of RHD gene copy number by the new array. Just a single discrepancy was observed,
serology D- to genotype D+. Genotyping results indicated that this individual had 1 copy
of RHD and this call was produced by 114 independent probesets. Further analysis of
genotyping results revealed the presence of two variants in the RHD gene of this individual,
LRG_796:c.697G>C and LRG_796:c.712G>A. In combination, these variants encode the
RHD*05.09 allele which is associated with variant expression of the D antigen (DV type
9). This could suggest that result in the electronic donor record is incorrect. A monoclonal
anti-D is used by NHSBT for routine D typing of donors and experts indicated mistyping
would be unlikely but not impossible for individuals carrying a variant RHD gene. A similar
D antigen mistype was recorded in the last 10 years by the NHSBT International Blood
Group Reference Laboratory (IBGRL), where tests using the standard monoclonal anti-D
failed to detect a similar phenotype (DV type 4). The RHD*05.04 (DV type 4) allele shares
the variant LRG_796:c.697G>C with the RHD*05.09 (DV type 9) allele suggesting that the
epitope for the monoclonal antibody may not be present on the RBCs of individuals with this
genotype.
Genotyping accuracy for some antigens, however, decreased when using the new assay.
RhC/c and RhE/e antigen genotyping accuracy decreased significantly to 42.93 and 76.93%
concordance for C/c and E/e, respectively. The original UKBBv1 array did not directly
interrogate the variants that encode C/c and E/e antigen expression but relied on “tagging”
variants that are in high LD with the phenotype encoding variant. While these ’tag-SNPs’
performed well, the decision to stop using them to infer antigen types was taken due to
the fact that the use of tag-SNPs is not an acceptable solution as LD was not 100%. In
translation, this means there would have been a hard-coded higher error rate in the bloodTyper
analysis algorithm for these antigens. Following this design choice, probes for typing the
variants that directly encode expression of C/c and E/e antigens, NM_020485.5:c.307C>T
and NM_020485.5:c.676C>G, were included on the 384 Blood Typing array. However,
genotypes for these variants were initially difficult to interpret.
Genotyping of Rh antigens is challenging due to high sequence homology between
the RHD and RHCE genes. This often causes miss-binding of array probes or erroneous
alignment of NGS sequencing reads. We developed novel algorithms to overcome these
difficulties (see Fig. 4.4).
Firstly, we used data from 114 copy-number probesets tiled across the RHD gene at loci
with the lowest sequence homology to the RHCE gene to ascertain RHD copy number. These
probes allowed us to accurately identify RHD copy number using the standard CNVmix
algorithm (Fig. 4.4a,b).
4.5 Stage 2 - Designing an array for donor genotyping 81
Secondly, genotype calling algorithms expect samples to gather in three clusters in
correlation to genotype. However, due to cross binding of RHCE probes to the RHD gene,
multiple overlapping clusters were observed for RHCE variants. Grouping samples by array
determined RHD copy number allowed us to identify that the degree of interference caused
by cross-binding is directly linked to RHD copy number. Three groups of clusters were
observed (Fig. 4.4c).
Thirdly, samples were split according to RHD copy number and genotypes for RHD and
RHCE variants were re-called for each copy-number sample group (Fig. 4.4d).
Application of this algorithm significantly increased concordance in the test set to 98·71%
and 99·61%, for the C/c and E/e Rh group antigens, respectively (Fig. 4.4e).
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Fig. 4.4 (a) Diagrammatic representations of the RHD and RHCE genes, the binding position
of array probes are indicated in red. The probes spanning RHD are used for RHD copy number
assessment and for RHCE, as an example, the probe for typing variant LRG_797:c.307C>T,
which is used for C/c typing. (b) All samples in the DIS-III cohort binned by RHD median
copy number probeset intensity ratio (log2), copy number clusters are annotated. (c) Geno-
type call plot for the C/c antigen variant, LRG_797:c.307C>T, in the RHCE gene. Samples
are coloured by array determined RHD gene copy number. Three unique sets of genotype
clusters can be observed, with a ’right shift’ in contrast linked to RHD copy number. (d)
Genotype call plots for the same samples and variant, LRG_797:c.307C>T, post copy number
stratified genotyping. (e) Improvement in Rh(C/c) and Rh(E/e) antigen typing concordance
resulting from application of the copy number genotyping algorithm.
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The N antigen also proved extremely challenging to type. All 109 discordances concern-
ing this antigen were serology N- to genotype N+. Inspection of bloodTyper calls excluded
an analysis pipeline issue, therefore discrepancy is caused by either the genotype calling
algorithm or due to a malfunctioning probeset. Molecular typing of N can be difficult be-
cause of sequence homology between the GYPA and GYPB genes. There is a region of 100%
sequence identity between the two genes where the variant controlling N expression in GYPA
is located. This biological artefact is responsible for the antibody determined phenotype
’pseudo N in people who are N-. Following the addition of copy number probes located in
GYPA and GYPB, the copy number aware algorithm used to improve RHD and RHCE variant
calling could be applied to N antigen typing. The probes used for N antigen typing were also
flagged for review and redesign in future array versions.
4.6 Stage 3: Large scale blinded trial of the UKBBv2 array
Guided by the results from the previous stages the donor typing content from the 384 Blood
Typing array was integrated into the original UKBBv1 array design.
We also added 9,180 variants in 49 genes relevant to antigen expression which had
minor allele frequencies (MAFs) >0.02% in large-scale sequencing datasets (see Table. 4.2).
These were included to ’future proof’ the array by capturing non-synonymous variants
with possible clinical consequences for antigen expression discovered in population scale
sequencing studies. This approach also allows us to link these variants to antigen expression
in future studies. The resultant Applied Biosystems UK Biobank – version 2 Axiom Array
(UKBBv2 array) has significantly increased content in the RBC and HPA antigen-encoding
genes (see Fig. 4.5).
In addition to physical array changes, algorithms were introduced to bloodTyper for
handling specific technical events. For example, in the event a probeset fails and therefore no
genotype is called for an important variant in the ABO locus underlying a group O phenotype,
such as LRG_792:c.261delG; no ABO antigen inference is made by bloodTyper for safety
reasons.
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Table 4.2 Genes relevant to antigen expression selected for coding variant enrichment on
UKBBv2 array
HGNC gene ID Inclusion Reason
A4GALT Blood Group Antigen
ABCG2 Blood Group Antigen
ABO Blood Group Antigen
ACHE Blood Group Antigen
ACKR1 Blood Group Antigen
AQP1 Blood Group Antigen
AQP3 Blood Group Antigen
ART4 Blood Group Antigen
B3GALNT1 Blood Group Antigen
BCAM Blood Group Antigen
BSG Blood Group Antigen
C4A Blood Group Antigen
C4B Blood Group Antigen
CD109 Platelet Antigen
CD151 Blood Group Antigen
CD31 Blood Group Antigen
CD44 Blood Group Antigen
CD55 Blood Group Antigen
CD59 Blood Group Antigen
CD99 Blood Group Antigen
CR1 Blood Group Antigen
ERMAP Blood Group Antigen
FUT1 Blood Group Antigen
FUT2 Blood Group Antigen
FUT3 Blood Group Antigen
GBGT1 Blood Group Antigen
GCNT2 Blood Group Antigen
GP1BA Platelet Antigen
GP1BB Platelet Antigen
GYPA Blood Group Antigen
GYPB Blood Group Antigen
GYPC Blood Group Antigen




KEL Blood Group Antigen
KLF1 Blood Group Antigen Related
RHAG Blood Group Antigen
RHCE Blood Group Antigen
RHD Blood Group Antigen
SEMA7A Blood Group Antigen
SLC14A1 Blood Group Antigen
SLC29A1 Blood Group Antigen
SLC4A1 Blood Group Antigen
SMIM1 Blood Group Antigen
XG Blood Group Antigen
XK Blood Group Antigen
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Fig. 4.5 Variation in antigen encoding genes compared to array content. Track (1-5) from
outside to inside, (1) representations of Red Blood Cell (RBC, red) and Human Platelet
Antigen (HPA, blue) antigen encoding genes, box length equates to the number of amino
acids in the protein. RBC and HPA system names are annotated next to gene labels; (2-3)
coding variants included on the UK Biobank (UKBB) v2 (crimson) and UKBB (teal) array,
respectively; (4) all coding variants with consequences in the gnomAD database (green); (5)
antigen encoding variants in the ISBT and IPD-HPA databases (red). Bar length for tracks
2-5 represents gnomAD alternate allele frequency.
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4.6.1 Selection of trial set samples and initial genotyping quality con-
trol
Following UKBBv2 array fabrication, we selected 7,477 blood donors from England
(n=4,795) and the Netherlands (n=2,682) who had consented to participate in the COMPARE
and DIS-III studies. DNA samples from these individuals were used as a ’trial set’ to validate
the UKBBv2 array.
In addition to blood donor samples, each array plate of 94 donor samples had two
HapMap DNA samples as controls included in it. These control samples have been exten-
sively genotyped and analysed by WGS. Samples NA19315 and NA19318 were included on
52 plates with the samples from the English donors, and samples HG00097 and HG00264
were included on 32 plates with the samples from the Dutch donors. This repeat genotyping
allowed us to assess array-wide repeat genotype concordance which was >99%, and concor-
dance with WGS genotype data which was >99% across all 168 repeated samples tests (see
Fig. 4.6).
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Fig. 4.6 (a) Array genotype concordance to next generation sequencing data across multiple
repeats of each sample for all typed variants. A drop in UKBBv2 array and WGS genotype
concordance can be observed for NA19315. This sample is from an individual of African
ancestry and it is therefore likely there is bias in the read alignment and genotype calling
for the WGS data. (b) Genotype repeatability across all repeats of each sample for all
typed variants. Samples NA19315 and NA19318 were used for the English donor samples
(blue) and repeat-tested 52 times each, and HG00097 and HG00264 used for the Dutch
donor samples (orange) and repeat-tested 32 times each, on separate genotyping runs. Grey
diamonds display means, middle box lines, box bounds and whiskers represent median, upper
and lower quartiles, and values spread beyond middle 50% of overall distribution are outliers
and represented by circles.
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As genotype concordance data from repeat testing of HapMap samples was excellent, we
proceeded with QC of the 7,477 trial set blood donor samples. 15 samples with imputed ver-
sus declared sex mismatches and more than five antigen typing discordances were identified.
Investigation revealed that these discrepancies were either caused by erroneous handling of
samples (n=4) or by incorrect data entry into the study database (n=11). The data from the
former category were excluded from further analysis (see Table. 4.3). Samples in the latter
category were retained following correction of sample linkage information. This left 7,473
samples for analysis in the final trial.
On further investigation, it was revealed that self-declared sex vs. genotype inferred sex
discordance arose for one sample as the contributing participant no longer identified with
their birth sex. In the case of this validation study, the sample was removed from further
analysis in accordance with study procedures as sex discordance analysis together with
discordance analysis for the ABO groups provides an added layer of quality assurance to
identify possible procedural errors, including sample handling errors. In practice, the BGC
recommends that sex mismatches should be treated as incidental ‘secondary findings’ and
not be reported back to the individual, except if explicit consent has been obtained.
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4.6.2 Allele frequency validation of the UKBBv2 array
The 7,473 trial set blood donors were each genotyped for 789,550 DNA variants using
the UKBBv2 array. 10,923 of these variants are used for inference of RBC, HPA and
HLA antigens. We compared the GRCh37 alternative allele frequencies (AAF) of the
genotyped variants for the 7,416 unrelated European ancestry donors in the trial set with the
corresponding AAFs measured by WGS in 8,510 unrelated European ancestry participants
in the NIHR BioResource pilot phase of the 100,000 Genomes Project. No significant
difference in AAF was detected for 99·02% of the 716,102 variants with MAF>0·01% in both
WGS and array data at a Bonferroni adjusted critical threshold (α=0.05/716,102, Fig. 4.7a,b).
Frequency comparison data for HLA, and RBC/HPA antigen typing variants is shown in
Fig. 4.7c-d. For 84 of RBC antigen typing variants measured AAFs differed significantly.
These variants were also given a priority ranking according to importance of phenotype, and
those identified as priority 1 (highest) variants were flagged for re-design in future validation
studies.
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Fig. 4.7 (a) A kernel density plot showing excellent average concordance between alternative
allele frequency in 7,416 UKBBv2 array typed unrelated European ancestry English donors
and 8,510 WGS typed unrelated European ancestry NIHR BioResource volunteers, across
the 709,713 variants with alternative allele frequency >0.1% in both datasets. (b) Bi-variate
scatter of the data used to generate the kernel density plot, emphasising outliers. Each red
arc corresponds to the critical threshold for a Pearson test of a given size comparing allele
frequencies in the two datasets, under the assumptions that genotypes were observed for
all participants and that Hardy-Weinberg equilibrium holds in both datasets. The arcs are
uniformly separated on a log-scale. (c) Variants in the HLA locus. (d) Variants encoding
RBC or HPA antigens.
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4.6.3 Overall antigen typing performance
Overall concordance between clinical and UKBBv2 antigen typing was 99·82% in 103,326
comparisons across 28 RBC antigens, 10 HPA antigens and 6 HLA loci for which clinical
typing data were available (see Fig. 4.8). All but 57 of the 7,473 donors enrolled in this study
were of European ancestry. Of the non-European ancestry individuals; 27, 21 and 9 were of
South Asian (SAS), East Asian (EAS4) and African ancestries, respectively. Antigen typing
concordance for these 57 individuals was 100% in 835 comparisons across 28 RBC and 10
HPA antigens compared.
Fig. 4.8 (a) Overview of concordance analysis and high-level categorisation of results. (b)
Concordance per antigen is shown as a percentage of the total number of comparisons (given
at the top of each bar) with concordant and discordant results in green and red, respectively.
(c) Categorisation by error type of discordances for the different RBC antigen systems and
for the HPA-5 system.
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4.6.4 RBC antigen typing performance
Concordance between RBC antigen typing results was 99·91% in 89,371 comparisons across
28 antigens (see Fig. 4.8a-b). We categorised the 72 (0·08%) remaining results according to
the reason for discordance (see Fig. 4.8a-c). 33 (45.8%) discordances were explained by erro-
neous clinical typing results. In 19 of these cases, variants encoding variant antigen expression
were detected by the array, examples include Del (RHD*11, NM_016124:c.885T), Kmod
(KEL*02M.01, NM_000420.2:c.1088G>A) and Fyx (FY*02W.01, NM_001122951.2:c.265C>T
and NM_001122951.2:c.298G>A). For carriers of these alleles, the chances of false-negative
antibody-based typing results are greatly increased. A unit of blood being erroneously
typed as negative for a given antigen may boost antibody levels in a previously sensitised
patient. The remaining 14 discordances in this category involved antigens where current
typing reagents have been known to give incorrect results (n=4) or where sequencing analysis
confirmed array genotyping results (n=10).
Sixteen of the discordances remain unresolved. However, in six of these cases previously
unobserved DNA variants, which were likely to underpin an antigen-negative phenotype
were discovered using the targeted sequencing platform designed for discordance resolution
(see chapter 5). The absence of these newly identified variants from the ISBT reference tables
prevents their use in antigen phenotype inference. To determine the effect of these six unique
variants functional antigen expression studies are required, therefore we regard these cases
as unresolved. For the remaining 10, we were unable to resolve the cause of the discordance
due to a lack of a DNA sample for further analysis. The cause of these discordances and the
genotyping method developed to investigate them will be detailed in chapter 5.
4.6.5 HPA antigen typing
A proportion of patients who are refractory to platelet transfusions due to HLA class I
antibodies also form HPA antibodies. For these patients, platelet concentrates lacking the
relevant HLA class I and HPA antigens are required. We report 99·96% concordance in 3,017
comparisons across 10 HPA antigens, with only a single discordant result observed for the
HPA-5a antigen (Fig. 4.8a-c).
4.6.6 HLA antigen typing
Most blood supply organisations maintain panels of HLA class I typed apheresis platelet
donors to support patients who are refractory to ABO-compatible platelet concentrates due
to HLA class I antibodies. Clinical HLA typing data were available for 1,221 of the 7,473
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trial set donors. Concordance between typing results across six HLA class I and II loci, at
two-field resolution, was 99·03% in 9,289 comparisons (see Fig. 4.9).
Fig. 4.9 HLA typing result comparison. Concordance per antigen is shown as a percentage of
the total number of comparisons (given at the top of each bar) with concordant and discordant
results in green and red, respectively. Concordance was assessed at group, string and allele
levels.
4.7 Impact of an extensively genotyped donor panel
For 7,473 trial set donors 37 RBC and 11 HPA antigens had at least one clinical typing result
available. These 48 antigens form a dataset that is representative of extended donor typing
programmes conducted on English and Dutch donors (Fig. 4.10a-b). In contrast to clinical
typing data, genotype inferred antigen typing is almost complete with only 458 (0·13%) of
354,624 possible results missing (Fig. 4.10c-d). Genotyping yielded 3.8 times more types
(47.9 vs 12.6 results per donor) compared to current practice. Genotyping also allowed us to
type the donors for 185 additional antigens for which no clinical typing results were available.
In total 1.2 million antigen types, on average 214.6/donor, were produced by genotyping.
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Fig. 4.10 Comparison of clinical and UKBBv2 array antigen typing availability in the trial
set of samples. Presence of colour represents presence of a typing result (positive or negative)
and absence of colour indicates lack of a typing result. (A-B) and (C-D) represent clinical
and UKBBv2 array typing data for English (blue) and Dutch donors (orange), respectively.
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To investigate the potential benefits of densely genotyping donors we used data from
patient referrals to NHSBT over a five-year period. Filtering this dataset for ’complex cases’,
defined as patients with alloantibodies against at least three different RBC antigens, produced
a set of 3,146 referrals with 1,253 unique alloantibody combinations (Fig. 4.11a). As expected,
we observed an inverse relationship between the probability of finding a compatible donor
and the number of alloantibodies identified in a patient (Fig. 4.11b). Using the trial set
of 7,473 donors as a ’virtual stock’, we report a 2·6-fold greater probability of identifying
ABO and RhD compatible donors who are negative for the relevant combination of antigens
needed to support patients with one of the 1,253 alloantibody combinations, when using the
genotype data. This translates to an additional 176 patients for whom a matched donor could
be identified. When finding donors for the most common alloantibody profiles, genotyping
data was equivalent to clinical typing data, but for the rare combinations genotyping increased
the average number of identified donors by 72 (Fig. 4.11c). We were even able to identify a
compatible donor for a patient with alloantibodies against nine different RBC antigens.
4.7.1 Identification of individuals with rare phenotypes
The ISBT defines a rare donor as one with a phenotype less frequent than 1 in 1000 in a
given population. This includes individuals negative for high frequency antigens (HFAs). On
average, NHSBT and Sanquin each type approximately 52,000 donors per year for HFAs
to identify those with HFA negative phenotypes. Fya-b-, k-, Lub-, and Vel- and Yta- are
examples of rare phenotypes that are in high demand. The genetic variants determining
these particular examples are typed by both the UKBBv1 and UKBBv2 arrays. Querying the
genotype data for 7,473 trial set donors identified 38 donors who lacked at least one of these
five HFAs. Expanding the query to the UKBB array typing data from 533,308 UKBB and
INTERVAL participants identified a further 8,951 individuals with potential HFA negative
blood types. This demonstrates that blood supply organisations could improve the supply of
rare blood types, for which level of demand is often a challenge, by typing donors with a
comprehensive DNA based test or recruiting from national scale genotyping studies where
data is readily available.
4.7.2 Immediate clinical benefit of extended typing data
Illustrating the clinical need for denser typing of donors, we present a female patient with
myelodysplastic syndrome and anti-E, anti-Cob and anti-Wra. Because of her bone marrow
failure she required regular transfusions, however, no suitable blood donors could be identified
in the 341,509 Dutch donors registered with Sanquin. Querying genotyping results from the
4.7 Impact of an extensively genotyped donor panel 97
Fig. 4.11 (a) Number of alloantibodies identified in patient samples, with number of patients
and antibodies on the vertical and horizontal axis, respectively. (b) Average increase in the
number of compatible donors when using UKBBv2 array instead of clinical typing data
to identify compatible donors, categorised by number of RBC alloantibodies identified in
patient samples. (c) Increase in the number of compatible donors when using UKBBv2 array
instead of clinical typing data for each complex alloantibody profile identified in the data
from 3,146 patients with RBC alloantibodies.
Table 4.4 Examples of rare blood group phenotypes and number of homozygous individuals
identified
Homozygous Negative Individuals
Phenotype rsID ISBT allele COMPARE DIS-III INTERVAL UK Biobank
Fy(a-b-) rs2814778 FY*01N.01 5 1 351 7427
k- rs8176058 KEL*01.01 7 1 73 variant uncalled
Lu(b-) rs28399653 LU*01 9 2 2 226
Vel- rs566629828 VEL*-01 1 0 3 104
Yta- rs1799805 YT*02 6 6 55 710
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2,682 Dutch donors in this study identified five compatible active Dutch donors and their
donations are now being used to provide life-saving transfusion support.
4.7.3 Donor and patient health information
Due to the large number of genetic variants typed by the UKBBv2 array, the utility of this
platform extends far beyond antigen typing for extended matching. For example, homozygos-
ity for the variant NM_000410.3:c.845G>A in the HFE gene is the most common cause of
hereditary haemochromatosis. A recent study showed that 21·7% of male and 9·9% of female
UKBB participants with this genotype presented with iron-overload pathologies. Using the
UKBBv2 array data we identified 78 (1%) donors in the trial set testing homozygous for this
variant. This information provides blood supply organisations with an opportunity to reduce
the risk of such pathologies developing in these individuals by recommending more frequent
donations.
Currently there is no approved process for returning genotype information such as this
back to donors and therefore the homozygous individuals identified in this study have not
been made aware of these results. We argue that due to the clinical significance of these
variants, the ease of typing for them using donor typing arrays, and the health benefits that can
be conferred to the individual that blood services begin to put in place the ethics, procedures,
and studies which will allow information on clinically actionable variants to be reported to
donors through appropriate channels.
4.8 Discussion
To ensure transfusion safety, blood is routinely matched for ABO and RhD compatibil-
ity. However, matching is not generally applied to other RBC antigens and each year
approximately 0.5 million patients become sensitised as a consequence.[88] These patients
subsequently require extended matching of blood to prevent HTRs, which are occasionally
lethal. This situation can become particularly precarious in transfusion-dependent patients
and it has been shown that extended matching from the beginning of transfusion support
brings immediate benefits by reducing the incidence of alloantibody formation.[96] To reduce
the frequency of this serious hazard of transfusion, some blood supply organisations have
introduced an extended matching policy for these patient groups. However, the cost of
implementing generalised extended matching policies will not be justified without conclusive
evidence from randomised trials of consequent reductions in morbidity or mortality. For
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such trials to be possible, a comprehensive and affordable extended antigen typing assay is
required to test large numbers of donors and patients.
Here we report a technology, already used to genotype millions of individuals, now
optimised for donor typing. We show by genotyping 7,473 donors, 99·92% concordance
between clinical and array antigen typing results in 103,326 comparisons across 44 clinically
relevant RBC and HPA antigens. We observed one HPA and 72 RBC discordances between
clinical and genetically inferred antigen type (0·08% of comparisons).
Currently there are no internationally recognised guidelines set for the validation of array
based high-throughput antigen genotyping tests. Therefore, the BGC has developed an initial
policy on how to deal with genotype-phenotype discordances in the event that genotyping
becomes standard of care in the future.
In short, the principles underlying this policy are:
First, international guidelines stipulate that ABO grouping has to be performed on every
donation. Considering the seriousness of ABO mismatched transfusions ABO typing will
remain antibody-based. The concordance testing between phenotype- and genotype-based
ABO grouping will be used as a quality assurance measure in addition to concordance
testing for sex. However the BGC will continue to resolve discordant results for ABO using
approaches outlined in my thesis.
Second, the international recommendation for typing blood cell antigens for systems other
than ABO is to perform these tests on two independently obtained samples of blood before
the results can be used in prescribing. The BGC entirely underwrites this recommendation
and foresees that with a comprehensive genotyping array these results will be generated far
more cost-efficiently for every donor. The results in Chapters 4 and 5 illustrate the methods
by which discordances can be investigated in case large number of donors are genotyped and
also shows a streamlined approach to resolving the discordances, respectively.
Third, in planning the next phase of the BGC four blood supply organisations (Australian
Red Cross Blood Service, NHS Blood and Transplant, New York Blood Centre and San-
quin) are placing Thermo Fisher GENETITAN instruments in their clinical laboratories. In
preparation of the study for obtaining FDA approval and CE-marking of the Axiom array
for blood cell antigen typing approximately 80,000 blood donor samples will be genotyped.
Based on the results presented in this thesis I expect that this will reveal approximately
600 discordances. By including samples from the South African National Blood Service
and from New York in this validation study larger numbers of samples of non-European
ancestry will be genotyped. It has been agreed that all the discordances will be resolved by
the approaches outlined in my thesis. As illustrated in this thesis the results of this resolution
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will, in a step-wise manner, improve the bloodTyper algorithm and the knowledge about the
genotype-phenotype link.
Fourth, if the Axiom array becomes an accredited and licensed diagnostic product then
the results will be used in a stratified manner based on the acceptability of error in antigen
typing, in the following categories:
• A quality assurance result only, e.g. the genotype determined ABO grouping results.
• A result which can be used for the labelling of units of blood, e.g. this would apply to
all common red blood cell antigens and selected set of the rare antigen types.
• A screening results which requires confirmation by an orthogonal antigen typing test,
which can be performed on the same DNA sample.
Fifth, the BGC foresees that if the Axiom test obtains regulatory approval then there
will be a transition phase in which there will be an immense opportunity to identify further
discordances. This is possible because of the wealth of extended typing data already available
to blood supply organisations. As an example, the four organisations which will introduce
genotyping next year jointly provide services for a population of approximately 120 million.
In aggregate, these services have a donor base of almost 2.5 million active donors. Genotyping
of 20% of these already registered donors would result in 0.5 M donor records with antigen
genotyping results. The results from Chapter 4 show that an estimated 75,000 of these donors
will have extended donor typing results. In addition in the UK the Early Disease Detection
Research Project UK (also named ADD) will genotype 5 M UK citizens. It is expected that
at least 0.5M of these study participants will be NHSBT donors.
Finally, the BGC has agreed to continue the analysis of discordant results after regulatory
approval has been obtained. If approval has been obtained Royalty funding will flow from
Thermo Fisher to the BGC providing funds to maintain the BGC collections of samples and
data and for resolving discordances. The results of the discordance resolution will be shared
in the public domain and made available to the International Society for Blood Transfusion
and the Histocompatibility and Immunogenetics Societies to support future improvements of
international standards for DNA-based blood cell antigen typing.
In conclusion, I foresee that by 2025 a tipping point will have been reached where
erroneous types generated by the current clinical typing tests will far exceed those made by
genotyping. I do however realise the important challenge of maintaining global collaboration
on data sharing, which is particularly important if donors of non-European ancestry are
genotyped at scale. As outlined above the BGC may provide the framework for continued
international collaboration.
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The question of whether extended typing of blood donors improves the efficiency of
matching blood units to patients with multiple RBC alloantibodies has been much debated.
We observed a 2.6-fold increase in the number of donors identified to support 3,146 complex
patients with multiple alloantibodies when extended genotyping data were made available.
The immediate clinical benefit of having densely typed donors is demonstrated by a female
patient with severe anaemia due to bone marrow failure, who required blood with an antigen
typing profile possessed by 1 in 400 donors. Notwithstanding this relatively high frequency,
no suitable donors were present in the Netherlands because donors are not routinely typed
for Coa and Wra because reliable or affordable typing reagents are lacking. Five compatible
Dutch donors were identified in the trial set of this work.
We did not alter the UKBB array content at the HLA locus because previous studies
suggest that HLA class I and II antigens can be imputed with good accuracy from the original
UKBB array data. However, the level of accuracy has never been empirically verified by
direct comparison of array versus clinical-grade HLA typing data.[69] We provide this
comparison and show excellent concordance at a 99·03% accuracy at two-field resolution.
Typing at this resolution has immediate value for the provision of HLA class I matched
platelet concentrates for refractory patients and shows that the platform if widely applied
could be used to improve the composition of platelet apheresis panels via identification of
donors homozygous for rare HLA class I haplotypes. Furthermore, the results can be used to
select donors with HLA haplotypes underrepresented in international bone marrow registries
for confirmation of their HLA type by next-generation sequencing.
We used the HFE locus to illustrate that the array data can also be used to inform policies
about donor health and confirm that approximately one percent of donors are homozygous
for the haemochromatosis causing variant in the HFE gene. Based on this observation
an estimated 12,000 individual donors in England and the Netherlands could donate more
frequently and reduce their risk of developing ill-health, whilst adding to blood stocks.
Reflecting the donor registries of The Netherlands and Britain, only 0.7% of donors avail-
able for this study were of non-European ancestry. Due to the low frequency of RH variant
antigens in European ancestry individuals and their high frequency in haemoglobinopathy
patients of African ancestry further validation must be performed before this test can be used
to clinically type these patients, and required donors, for variant antigens. However, the
complete concordance between 835 antigen typing results for the 57 non-European ancestry
individuals and identification of two erroneous serological typing results due to variant RhD
expression reported here provides justification for further studies using samples from donors
and patients recruited by ancestry and specific blood antigen types.
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All together we present an affordable genotyping assay capable of simultaneously typing
all clinically relevant human red blood cell group antigens that has been trialled using
thousands of blood donors. As the study was embedded in the national blood services
of England and The Netherlands, we were able to take a first look at how high-volume
comprehensive donor typing can be used to simplify the provision of compatible blood for
sensitised patients with alloantibodies against multiple red blood cell antigens.
With many health care systems making preparations for the era of precision medicine, an
increasing number of countries are genotyping a proportion of their population. The assay
presented here is nested within the platform already used by the FinnGen Biobank, Million
Veteran Program, Taiwan Precision Medicine Initiative, and the impeding UK 5 Million
studies. This means that full blood cell antigen types will become available for millions of
individuals, providing blood supply organisations with the opportunity to implement a policy
of genomics-based transfusion medicine.
Chapter 5
Typing genetically complex antigens
5.1 Abstract
In this chapter, we present the Blood transfusion Genomics Capture (BGC) capture assay
that is designed for the targeted sequencing of the genes underlying the blood cell antigens in
humans. The BGC capture assay design includes all consensus coding sequence and 5’ and
3’ UTRs present in Ensembl and RefSeq for the 54 relevant Red Blood Cell (RBC), Platelet
(PLT) and Neutrophil (NEUT) antigen encoding genes. This next-generation sequencing
(NGS) test has been used by the BGC to aid the resolution of the discordant results between
the blood cell antigens inferred from UK Biobank version 2 (UKBBv2) genotyping results
and the clinical antigen types that we reported in Chapter 4. The test also targets the
regulatory elements (REs) that control these genes as determined by the BLUEPRINT of
Haematopoietic Epigenomes project and by BLUEPRINT-related studies which aimed to
identify the long-range interactions between gene promoters and these REs.[83, 101, 84]
In total 1,094,363 bp are targeted for sequencing by the BGC capture NGS assay and this
discontinuous genomic space is referred to as regions of interest (ROI) hereafter.
Two validation experiments were carried out to determine the performance of the assay;
In one, 48 samples for which whole-genome sequencing data at 30x coverage (WGS) were
available and the samples were also sequenced using the BGC capture assay, followed by a
direct genotype to genotype comparison. In the other, DNA samples from 24 NHSBT blood
donors were tested on the BGC assay and the genotype-inferred antigen types were compared
with the antigen types retrieved from electronic donor records. Excellent concordance was
observed in the validation experiments between results for both genotype (99.65%) and
phenotype (99.05%).
We then used the BGC capture assay to sequence DNA samples for which we reported
discordance between UKBBv2 array and clinical antigen typing results in Chapter 4. The
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73 discordances reported in the previous chapter were observed in the results for 69 donors,
with DNA samples for 61 of them being available for recall and BGC capture sequencing.
The bloodTyper algorithm was used to infer antigen types from the BGC capture data and a
three-way comparison between UKBBv2 array, BGC capture, and donor record antigen types
were performed. In addition, the genetic antigen typing reports and the donor record antigen
typing reports were reviewed by experts from the BGC and the donor typing laboratories of
NHSBT and Sanquin.
With this approach, the cause of 78% of discordances could be identified. Hence the
BGC capture assay is a viable second-line test for the resolution of discordances between
UKBBv2 array inferred and clinical antigen types. We also show that the capture test has
some advantages for resolving discordances over alternative capture tests like WES.
5.2 Introduction
To continue improving the design of array-based donor genotyping assays and accompanying
blood group interpretation software, it is essential to further investigate samples for which
discordances between genotype and phenotype are observed. There are several possible
reasons for discordances between array genotype inferred antigen typing results and antigen
types obtained by currently used typing tests, which are mainly antibody-based tests for red
blood cell (RBC) antigens;
The first concerns individuals with de novo variants that control antigen expression or
novel combinations of known antigen encoding variants which have not been documented
by the ISBT. For the former, previous studies suggest we can expect approximately 70 de
novo variants per generation with 90% being single nucleotide polymorphisms (SNPs), 9%
being short insertions or deletions (indels), and 1% being structural variants (SVs) - there is
no way to preemptively include these variants on array designs and they will therefore go
untyped.[53] For the latter, algorithmic inference of blood type is extremely difficult as the
link between phenotype and genotype is incomplete and limited haplotype frequency data is
available to allow accurate phasing of the variants.
The second concerns antigens for which it has been widely reported that types determined
by haemagglutination using commercially available or in-house typing reagents may be
erroneous. Weak expression of an antigen, expression of a rare variant antigen and contami-
nation of polyclonal typing reagents with other specificities are well-documented causes of
erroneous types.
The third involves the incorrect calling of genotypes. In the case of arrays we have
already reported in chapter 4 that in some cases array probes simply do not work and have
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to be excluded from analysis, and that on some array designs probes for genotyping critical
antigen defining variants are entirely lacking.
Finally, the calling of structural variants (SVs) from array genotyping data remains
challenging and from most types of sequencing data. To reliably call SVs breakpoints must
be characterised at nucleotide resolution. It is particularly difficult to accurately type SVs
using array data as when DNA is hybridised to probes on the array it has been fragmented
and only a single nucleotide position is interrogated. This means that although genotyping of
specific variants is possible post DNA fragmentation, information about genome structure is
lost (see Fig. 5.1).
Fig. 5.1 Cartoon showing how genome structure information is lost in the array genotyping
process. (a) Example genotyping of a gene with regular structure. (b) Example genotyping
of a gene with exons 2-6 inverted. Here it can be seen that fragmented sections of the gene
hybridise to the array in their correct positions regardless of original gene structure. Although
individual sites in exons 2-6 of both genes would have genotyped correctly, structural
information is lost.
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The limitations of the array with respect to the identification of SVs require careful
consideration when inferring antigen status. In chapter 4 we showed that reliable calling of
the deletion type SV which underpins the D-negative phenotype required specific alterations
to the array design and bloodTyper algorithm. Specific array designs and algorithms for the
38 other phenotypes that we know are encoded by complex SVs do not exist, and therefore
they cannot currently be typed array-based technology (see Table. 5.1). The same applies to
novel SVs which have not yet been linked to antigen expression.
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Table 5.1 ISBT alleles which cannot be typed using current array technologies
System ISBT Allele Molecular Configuration
FUT2*0N.03 Fusion gene between FUT2 and SEC1
H
FUT2*0N.04 Fusion gene between FUT2 and SEC1
GYP*101.01 GYPA:c.233_271del with GYPB translocation
GYP*101.02 GYPA:c.232G>A with GYPB translocation


















GYPA*01N GYPA:c.38_453del and GYPB:c.1_37del
GYPB*01N GYPB:c.38_276 and GYPE:c.1_37del
MNS
GYP*01N GYPA:c.38_453del;GYPB:c.1_276del
RHCE*01.29 RHD exon 4-9
RHCE*01.34 RHD exons 4-7
RHCE*03.02 RHD exons 2-3
RHD*01N.07 RHCE exons 4-7
RHD*01N.42 RHCE exons 1 and RHCE exons 7-10
RHD*01N.43 RHCE exons 1-3
RHD*01EL.23 RHCE exons 5-7
RHD*01EL.44 RHCE exons 4-9
RHD*01N.02 RHCE exons 1-9
RHD*01N.03 RHCE exons 2-9
RHD*01N.04 RHCE exons 3-9
RHD*01N.05 RHCE exons 2-7
RH
RHD*01N.06 RHCE exons 4-7;c.733C>G;c.1006G>T
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In previous work we have shown that sequence data generated by WGS and WES can
be used for the accurate and comprehensive typing of blood cell antigens and studies have
documented the use of WGS to discover and confirm the link between genotype and antigen
expression.[102] Due to the ability of short-read Illumina NGS to genotype almost any
position in the genome, thus being able to genotype novel variants, the technology could
be applied as a second-line test to investigate discordances reported by first-line screening
assays such as the UKBBv2 array.
Currently, the cost per sample of WGS is still too high for its widespread use by blood
supply organisations for resolution testing. WES is a cheaper option than WGS, however,
these assays are not designed with antigen typing in mind and often do not adequately
sequence regions of the genome important for blood cell antigen typing (see Fig. 5.2).
Furthermore, a recent comparison of the quality of WES data sets against the ‘gold’ standard
coverage of WGS showed a significant difference in sensitivity for detecting SNVs and indels
between different laboratories providing WES services.[60]
Targeted sequencing tests present a third short-read NGS option. The underlying principle
of the test is similar to WES, differing in that the baits used to capture the region of interest
(ROI) are customised and application-specific. The cost and turn-around-time of capture
sequencing tests are similar to WES, and because the ROI is much more specific and on
average 50 times smaller than for WES, very high sequencing coverage can be achieved for
the ROI.
Fig. 5.2 Read depth profiles of Targeted, Whole Exome and Whole Genome sequencing
across the ABO gene of the same DNA sample. The gene structure of ABO is shown in blue
at the bottom of the figure, thick and thin sections represent exons and introns, respectively.
A red box is drawn around exon 1 to highlight the poor coverage of WES in this region.
In this chapter, we detail the development, validation and use of the BGC capture NGS
assay. We show its utility in identifying the cause of most of the discordances observed in
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Chapter 4 between UKBBv2 inferred antigen types and clinical antigen types retrieved from
the donor record.
5.3 Chapter workflow
In order to investigate samples producing discordant results by array technology, we de-
veloped the BGC capture NGS assay. This assay is a targeted sequencing test designed to
sequence genes underpinning RBC, PLT and NEUT antigen expression. The work reported
in this chapter has been split into three stages (see Fig. 5.3).
Firstly, the assay was designed by overlapping knowledge from the Transfusion Medicine
field with the data produced by population genomics and epigenomics studies.
Secondly, we performed two validation experiments - one in which samples were se-
quenced using the BGC capture NGS assay and resulting genotypes were compared with
clinical-grade WGS data, and another in which DNA samples from NHSBT blood donors
were sequenced using the BGC capture assay and their genotype-inferred antigen types
compared to the clinical ones held in the electronic donor record.
Finally, we sequenced DNA samples for which discordances were observed in our
previous UKBBv2 array experiment described in chapter 4. The cause of the discordant
results was then investigated on a case by case basis.









































Fig. 5.3 Cartoon representing the overall workflow of this chapter. From top to bottom;
(Design) Sequencing targets were identified using multiple data sources and combined to
produce a unified list of sequencing targets for which capture baits were then synthesised.
(Validation) Two separate validation experiments were carried out, one in which we com-
pared BGC capture genotype results to those generated by WGS and another in which we
compared antigen types inferred using the BGC capture NGS assay to the clinical ones
obtained from the electronic donor record. (Use) The BGC capture assay was then used for
its intended purpose, to resolve discordant results between the UKBBv2 inferred antigen
types and clinical antigen types.
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5.4 Assay design
The BGC capture NGS assay is designed to sequence all 54 (in 2018) relevant RBC, PLT
and NEUT antigen encoding genes identified by the BGC panel of experts. It was decided
for 22 genes to capture the entire gene body (exons and introns) and the 1000 bp upstream of
the transcript start sites (named complete coverage hereafter). For the remaining 32 genes
the consensus coding sequence (CCDS), the 5’ and 3’ UTRs present in Ensembl and RefSeq
and the 1000 bp upstream of the transcript start sites are targeted (named exon coverage
hereafter). The decision whether to apply complete or exon only coverage was based on a
ranking of the clinical importance of the antigen systems, the complexity of the relationship
between gene sequence and antigen expression, and the size in bp of the entire gene body
(see Table. 5.2). We also targeted the REs identified in human erythroblasts and known to
physically interact through long-range interactions with the promoters of the genes known
to be relevant for RBC antigen expression.[101, 84] Additionally, the HBB gene is targeted
so that the BGC assay results can also be used to determine whether a DNA sample carries
the minor allele of variant rs334, which if present in homozygosity is causal of Sickle Cell
disease. The final design was reviewed by several BGC experts and in total the targeted ROI
for capture and sequencing is 1,094,363 bp.
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Table 5.2 BGC capture target genes
HGNC symbol System / Group Antigen Type Coverage selected
ABO ABO RBC Complete
GYPA MNS RBC Complete
GYPB MNS RBC Complete
GYPE MNS RBC Complete
RHD Rh RBC Complete
RHCE Rh RBC Complete
BCAM Lutheran RBC Exon
KLF1 Lutheran RBC Complete (gene <10kb)
KEL KEL RBC Exon only
FUT3 Lewis RBC Complete (gene <10kb)
ACKR1 Duffy RBC Complete and GATA-1 binding site
A4GALT P1PK RBC Exon
SLC14A1 Kidd RBC Exon
SLC4A1 Diego RBC Exon
ACHE Cartwright RBC Complete (gene <10kb)
CD99 Xg RBC Exon
XG Xg RBC Exon
ERMAP Scianna RBC Exon
ART4 Dombrock RBC Exon
AQP1 Colton RBC Exon
ICAM4 Landsteiner Wiener RBC Complete (gene <10kb)
C4A Chido Rodgers RBC Exon
C4B Chido Rodgers RBC Exon
FUT1 H RBC Complete (gene <10kb)
XK Kx RBC Exon
GYPC Gerbich RBC Complete
CD55 Cromer RBC Exon
CR1 Knops RBC Exon
CD44 Indian RBC Exon
BSG Ok RBC Exon
CD151 Raph RBC Complete (gene <10kb)
SEMA7A John Milton Hagen RBC Exon
GCNT2 I RBC Exon
B3GALNT1 Globoside RBC Exon
AQP3 Gill RBC Complete (gene <10kb)
RHAG Rh-associated glycoprotein RBC Exon
GBGT1 Forsmann RBC Exon
ABCG2 Junior RBC Exon
ABCB6 LAN RBC Complete (gene <10kb)
SMIM1 VEL RBC Complete
CD59 CD59 RBC Exon
SLC29A1 AUG RBC Exon
FUT2 Secretor RBC Complete (gene <10kb)
ITGB3 HPA-1,4,6,7,8,10,11,14,16,17,19,21,23,26,29 HPA Exon
GP1BA HPA-2 HPA Complete
ITGA2B HPA-3,9,20,22,24,27,28,Lapa HPA Exon
ITGA2 HPA-5,13,18,25 HPA Exon
GP1BB HPA-12 HPA Complete (gene <10kb)
CD109 HPA-15 HPA Exon
FCGR3B HNA-1 HNA Complete (gene <10kb)
CD177 HNA-2 HNA Complete (gene <10kb)
SLC44A2 HNA-3 HNA Exon
ITGAM HNA-4 HNA Exon
ITGAL HNA-5 HNA Exon
HBB - Sickle Cell 400 bp region covering - NM_000518.4:c.20A>T
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5.5 Validation of BGC targeted sequencing assay
Following the selection of targets, the BGC capture NGS assay design was submitted to
ROCHE NimbleGen, Inc. (Madison, WI) and DNA baits were produced. We then used these
baits to perform two validation experiments.
5.5.1 Comparison to WGS data
DNA samples from 48 individuals enrolled in the NIHR BioResource and for whom 30x
WGS was already available were selected at random and sequenced using the BGC capture
NGS assay. Sequence reads were aligned to the GRCh37 reference sequencing using BWA
0.7.10. These alignments were used to assess the coverage profile produced by the BGC
capture assay. The average read depth for the entire ROI across all samples was 696.54
(range 0 to 2356.290). Overall coverage of the target region was 99.2% at >30x read depth
(see Fig. 5.4a). Coverage of all regions relevant for blood cell antigen typing was 99.91% at
>30x read depth and 100% at >15x read depth. We also calculated the sequence coverage
profile for each base of each target gene for the 48 samples, which were multiplexed in a
single sequencing batch (see Fig. 5.4b). This showed that the antigen encoding space of each
individual sample was covered adequately.
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Fig. 5.4 Sequencing coverage of blood cell antigen ROI for the BGC capture NGS assay. (a)
Distribution of average read depth across the 48 samples for all targeted bp in the ROI of the
BGC assay. (b) Read depth across the 48 samples for each bp in genes relevant for antigen
expression on RBCs.
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SNVs and indels were called for each of the 48 samples using GATK 3.3 HaplotypeCaller.
Sex was then inferred using two statistics based on sequence reads aligned to well-covered
target regions (>95% of samples covered at 30x): the ratio between heterozygote and non-
reference homozygote genotypes (het/hom) on the X chromosome sites, and the ratio between
the median coverage on X and the median coverage on the autosomes (aut/X).[103] The
het/hom ratio is computed using heterozygote SNVs with an allele depth between 0.3 and
0.7 to guard against errors. No discordant results were observed when comparing genetically
inferred sex for each of the 48 samples versus the self-declared sex, and all were progressed
to the next stage of analysis.
Genotype to genotype comparison was then performed between the sequencing results
obtained by the BGC capture array and by WGS for each of the 48 samples. Samtools 1.9
was applied to extract reads mapped to the BGC capture ROI from the WGS alignments for
each individual. The sequence reads for all samples from the two different sequencing tests
were then individually re-aligned to the GRCh37 reference sequence using BWA v0.7.10 and
variants were called from subsequent alignments with GATK HaplotypeCaller v3.3 using
standard parameters. A stringent filtering step (Mean Mapping Quality < 40.0 || Quality by
Depth < 2.0 || Fisher Strand > 100.0 || HaplotypeScore > 13.0 || Mean Quality Rank Sum <
-12.5 || Read Position Rank Sum < -8.0) was applied to all variants observed to reduce the
chance of erroneous variant identification. Variants passing QC filters for all samples were
then merged into technology respective variant call-sets, one named the BGC capture variant
call-set and the other the WGS variant call-set. Both call-sets were trimmed by removing
variants with <99% overall genotype call rate and then an intersection performed to ensure
that each had identical variant contents. This left a total of 3,689 variants (3356 SNVs, 332
indels) for the final comparison experiment.
Concordance between genotypes was 99.65% (172,921 correct in 173,528 comparisons).
For 401 (66%) of the 607 discordant genotypes the cause of the error seemed to be due the
WGS results, where a sample with a major/minor genotype had been identified as major/major
instead - this type of error is expected as the BGC capture NGS assay platform produces
much higher read coverage in the ROI compared to WGS (see Table. 5.3). It is therefore a
more sensitive test for calling the presence of a minor allele, in particular for regions where
coverage of a region by WGS is below 30 reads. The discordance of the remaining 206
genotypes (34%) was most commonly caused by lower quality mapping of reads which in
Illumna NGS can occur for numerous reasons that are previously reported.[104] No variants
for which discordant genotyping results were observed between the BGC assay and WGS
were at variant positions associated with antigen definition according to the ISBT or IPD
databases for RBC and HPA antigens, respectively.
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Table 5.3 Genotype to genotype comparison between BGC capture and WGS data
BGC capture
MM Mm mm no call
WGS
MM 103753 410 15 371
Mm 31 55335 151 619
mm 0 0 13833 1487
no call 14 28 99 0
After having observed that the BGC capture NGS assay could accurately measure geno-
types in the antigen typing space, we next sought to validate the assay for its ability to
correctly produce genotypes from which to infer antigen types.
5.5.2 Comparison to clinical antibody typing
DNA samples from 24 NHSBT blood donors enrolled in the NIHR BioResource were
selected due completeness of RBC antigen typing data in their electronic donor record and
availability of an adequate amount of DNA in the NIHR BioResource sample repository. The
24 DNA samples were retrieved from the repository for analysis by the BGC capture NGS
assay. Sequence reads were aligned to the GRCh37 reference sequencing using BWA 0.7.10.
Average read depth over the ROI for the 24 samples was 524.22 (range 0 to 2106). Overall
coverage of the ROI was 98.7% at >30x read depth. Coverage of the antigen typing specific
ROI was 99.89% at >30x read depth and 100% at >15x read depth. Sex was inferred from
genotype using the method described in the previous validation step and the results were
concordant with self-declared sex for the 24 samples.
Alignments of the sequence reads were analysed using the bloodTyper exome sequencing
pipeline with limited modifications to adjust for the increased read depths of the BGC assay
results compared with those from WES. Inferred blood cell antigen types were compared to
the clinical ones retrieved from the electronic donor record.
Concordance between BGC capture assay inferred and donor record antigen types was
97.94% in 535 comparisons across 24 RBC antigens for which clinical typing data was
available (see Fig. 5.5).
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Fig. 5.5 Concordance between BGC capture inferred and donor record antigen types. Con-
cordance per antigen is shown as a percentage of the total number of comparisons, given at
the top of each bar, with concordant and discordant results in green and red, respectively.
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Investigation revealed that 7 of the 11 discordances were identified for a single sample
with discordant typing results for the ABO, D, M, s, Lua, Fyb, Jkb antigens. The most likely
cause of this large number of discordances in a single sample is an error in data transfer or
more likely an error in sample handling in one of the many sample handling steps between
blood donation and generation of the BGC assay and WGS genotypes. Sanger sequencing
of a selection of variants unique to the sample confirmed that the DNA retrieved from the
sample repository was the same as the sample sequenced in this experiment. Without any
further way of investigating the discordance between our results and those on donor record,
we decided to remove this sample from further analysis. After removal of the aberrant sample,
four discordant results remained for four different samples. Three of these concerned C/c
antigen typing results. C/c antigen typing by NGS requires a specific algorithm, in brief;
The variant controlling C/c expression lies in exon 2 of RHCE and homology between RHD
and RHCE means variant calling by NGS in this region can be unreliable. The C genetic
configuration of RHCE is more homologous to RHD exon 2 than the c configuration. Due
to increased homology and an artefact of alignment algorithms, NGS sequence reads for
RHCE exon 2 will map to RHD exon 2 for individuals carrying the C encoding variant.
bloodTyper exploits this biological/technological artefact to type the C/c antigens by looking
for deviations in read depth ratios across RHD and RHCE exons (see Fig. 5.6).
Following inspection of the average read depth ratios produced by the BGC capture
assay across RHD and RHCE a small adjustment was applied to the bloodTyper algorithm to
calibrate it, this resulted in the three discordances for C/c typing being corrected.
Fig. 5.6 Cartoon showing differences in read depth profile for different C/c antigen phe-
notypes. (Top) For a C-c+ phenotype sample, uniform read depth can be observed across
all RHD and RHCE genes. (Bottom) For a C+c- sample, an increase in read depth over
RHD exon 2 and decrease in read depth over RHCE exon 2 can be observed as a result of
erroneous mapping of RHCE reads to RHD due to sequence homology. bloodTyper exploits
this artefact to enable C/c antigen typing from NGS data.
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The fourth and final discordant result concerns the Jkb antigen. This sample was Jkb+ by
antibody typing and Jkb- by genotype. Inspection of the raw sequencing data did not reveal a
reason for this discordance. The variant for Jka/b typing, chr18:43,319,519G>A, was covered
by 1161 unique reads (see Fig. 5.7). There is a possibility of allele drop-out with capture
sequencing platforms, however it is unlikely in this case as other samples heterozygous for
this variant have been detected correctly using the BGC capture assay. There was not enough
DNA in the sample repository to perform analysis by an alternative sequencing approach,
therefore the discordance for this donor remains unresolved. Expert members of the BGC
consider it highly likely that the antibody determined antigen type may have been erroneous.
Fig. 5.7 Screenshot of the BGC capture bloodTyper report for the Jkb discordant sample.
100% coverage of the SLC14A1 gene exons can be observed. 0 alternate reads were detected
at the Jka/b antigen defining site.
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The results of the two validation experiments show that the BGC capture NGS assay can
accurately measure genotypes across the entire ROI and that accurate antigen typing results
can be inferred from the genotyping data produced. We proceeded to use the assay for its
intended purpose, investigation of the DNA samples for which discordance was observed
between UKBBv2 array and clinical antigen typing results.
5.6 Investigation of discordant array samples
In chapter 4 we reported 73 discordant results in 69 samples; for 67 only a single discordant
antigen typing result was observed and two samples had two discordant results each. New
aliquots of DNA were retrieved from the NIHR BioResource archive for 61 of the 69 samples
(for the eight remaining samples the DNA stocks were inadequate). The 61 recalled DNA
samples were sequenced using the BGC capture NGS assay and sequence reads were aligned
to the GRCh37 reference sequence using BWA 0.7.10. The average read depth across the
ROI for all samples was 489.11 (range 0 to 1650.54). Overall average coverage of the ROI
was 99.1% at >30x read depth. Coverage of the regions specific to antigen typing was 99.93%
at >30x read depth and 100% at >15x read depth for all samples. Genetically inferred sex
versus self-reported sex was concordant for all samples.
bloodTyper was used to infer antigen types for each sample and a three-way comparison
between UKBBv2 array inferred, BGC capture inferred, and electronic donor record antigen
typing results was performed. Manual analysis of the genetic typing result was conducted
by three independent experts of the BGC and all clinical antibody typing results from the
electronic donor record were reviewed with experts from the typing laboratories of NHSBT
and Sanquin.
Using the results of the BGC capture NGS platform we were able to identify the cause
for all but 16 of the total 73 discordant results (see Fig. 5.8). Individual reports detailing the
analysis of each discordant case are given in supplemental table 1 in the appendix of this
thesis.
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Fig. 5.8 Breakdown of discordant UKBBv2 samples according to reason for discordance and
blood group system.
5.6.1 Algorithmic discordances
6 (6.9%) of the discordant results were caused by limitations of the bloodTyper algorithm
version used for this analysis.
Four samples were ABO group O according to the electronic donor record and group
A according to the results obtained with the UKBBv2 array. The UKBBv2 array detected
heterozygous group A phenotype (ABO*A1.01) and group O phenotype (ABO*O.01.01)
haplotypes for each of the four samples, leading to an overall group A typing result. Upon
sequencing of these samples using the BGC capture assay, we identified additional het-
erozygous genotypes for the variants NM_020469.2:c.646T>A, NM_020469.2:c.681G>A,
NM_020469.2:c.771C>T, and NM_020469.2:c.829G>A in the ABO gene.
Alone these variants usually encode an Aweak phenotype, however, when observed
alongside another O phenotype (ABO*O.01.01) allele, as is the case in these samples, the
variants underpin a second O phenotype (ABO*O.09.01/2) resulting in an overall group O
typing result. Inspection of raw UKBBv2 array data revealed that all of these variants were
accurately called in the affected samples. However, at the time of the UKBBv2 analysis
detection of variant antigens, including Aweak, was disabled in the bloodTyper array analysis
workflow to simplify comparison to donor records. This means that an incorrect result for
these samples was reported. Variant antigen typing has since been enabled and these four
discordances were resolved.
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Additionally, bloodTyper reported Jkb positive typing results for two samples that were
serologically Jkb negative. In both cases heterozygous genotypes were observed for the
variant NM_015865.7:c.342-1g>a which underpins the Jknull phenotype (JK*01N.06). Cur-
rently, the bloodTyper algorithm does not use this variant to infer phenotype due to lack of
haplotype frequency data - in layman’s terms, the algorithm will not decide if Jka or Jkb is
nullified for safety reasons. Instead, it issues a warning when the variant is detected that
antibody-based confirmation of the Jk typing results is required.
5.6.2 Array discordances
18 (24.7%) of the discordant results were due to array genotyping errors which can be
subdivided into three categories: Incorrect genotype calls (n=5): For three ABO and two
RH (e) antigen discordances incorrect genotypes were reported by the UKBBv2 array. In
these cases, array genotype call confidence was barely above the QC threshold. Inspection
of call plots revealed these calls were positioned almost exactly between cluster boundaries.
BGC capture antigen typing results were in concordance with donor record typing results
for these five samples, and the correct genotype calls were observed. Increasing UKBBv2
array genotype call QC thresholds eliminated these errors by producing no genotype call for
affected variants in these samples. bloodTyper would then subsequently not infer antigen
status and in practice, these samples would be flagged for re-genotyping or typing via
alternative methodology.
Probeset issues (n=5): For these cases, the BGC capture antigen typing results were
in concordance with donor record typing results for these samples, and the BGC assay
genotyping results did not concur with those reported by the UKBBv2 array. This prompted
inspection of the array genotype call plots and revealed that the probes, whilst performing
adequately, required further re-design to increase cluster resolution. The M, N, S and s
antigens were those affected by this type of error.
Lack of optimum typing variants (n=8): All cases here concerned typing results for the
C antigen of the RH system. The BGC capture assay antigen typing results were in concor-
dance with donor record typing results for these samples, and genotypes reported prompted
inspection of UKBBv2 array raw genotyping data. Currently, C antigen status is inferred
using the variant NM_020485.5:c.307C>T, which directly encodes antigen expression. Many
DNA-based technologies fail to accurately type this variant due to extremely high homology
between the RHD and RHCE genes, particularly in exon 2 where this variant is localised.
A 109 bp insertion in intron 2 of the RHCE gene, located at NC_000001.10:25732083-
25732084 (GRCh37), which has been classically used for DNA-based C antigen typing has
no working probeset on the UKBBv2 array. Using two confirmatory variants for C typing is
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the best strategy to improve accuracy. Improved probesets for typing the 109 bp insertion has
been included in the next version of the array.
5.6.3 Error in donor record antigen typing data
33 (45.8%) discordances were explained by erroneous clinical typing results. These errors
can be subdivided into two categories:
Individuals with variant antigen expression (n=19): In 19 of these cases, alleles encoding
variant antigen expression were detected by the array. Examples of these include the Del
(RHD*11, NM_016124:c.885T), Kmod (KEL*02M.01, NM_000420.2:c.1088G>A) and Fyx
(FY*02W.01, NM_001122951.2:c.265C>T and NM_001122951.2:c.298G>A) phenotypes.
For carriers of these alleles, the chances of false-negative antibody-based clinical typing
results are greatly increased. The BGC capture assay antigen types and corresponding
genotypes confirmed the results from the UKBBv2 array for these samples. A unit of blood
being erroneously typed as negative for a given antigen, may boost antibody levels in a
previously sensitised patient. We therefore reported these erroneous clinical typing results to
the relevant blood services for follow-up investigation.
Error in clinical typing data (n=14): The remaining 14 discordances in this category
involved antigens where current typing reagents have been known to give incorrect results
(n=4) or where the BGC capture assay analysis confirmed array genotyping results (n=10).
The most likely reason for discordance being erroneous clinical typing data.
5.6.4 Unresolved discordances
16 (21.9%) of the discordant cases remain unresolved. For six of cases, previously unobserved
DNA variants which were likely to underpin an antigen negative phenotype were discovered
using the BGC capture assay. The absence of these newly identified variants from the ISBT
reference tables prevents their use in antigen phenotype inference by bloodTyper and these
variants were not included in the UKBBv2 array design. To determine the effect of these six
unique variants on antigen expression functional expression studies are required, therefore
we regard these cases as unresolved. For the remaining 10 discordances we were unable to
resolve the cause of the discordance due to lack of DNA samples for further analysis.
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5.7 Discussion
In this chapter we presented the results obtained with the BGC capture assay, a novel targeted
sequencing platform designed as a second-line test for resolving discordances between
UKBBv2 array-based antigen typing results and the typing results from the electronic donor
record. In order to validate the platform, we compared the data produced by the assay against
WGS genotype data and against clinical antigen phenotyping data. Excellent concordance
was observed between results at both genotype (99.65%) and phenotype (99.05%) resolution,
following removal of one erroneous sample.
The BGC capture assay proved to be an indispensable tool for investigating and resolving
most of the discordant results. We were able to resolve 78% (57 / 73) of discordances
between UKBBv2 array and donor record antigen types. In the unresolved cases, we were
able to identify 6 previously unobserved DNA variants, which are likely to underpin altered
antigen phenotypes in 6 of the 16 discordant cases. For 10 donors we were not able to use
the BGC assay due to a lack of DNA for further analysis.
Most commonly the BGC capture assay was used as an orthogonal confirmatory test
either confirming array-based genotyping results or allowing for the identification of falsely
reported genotypes. In several cases, the NGS data produced by the BGC capture assay
revealed UKBBv2 array probesets that were passing standard QC filters, yet still reporting
false ’borderline’ genotype calls. This information can now be used to set array genotype
calling confidences for those probes or to indicate that they need re-design. This will further
improve the typing accuracy for all antigens concerned in future array designs.
Most importantly, in the cases we regard as still ’unresolved’ the BGC capture assay has
identified novel variants that could explain the genotype/phenotype discordance. Although
these variants are not known to the ISBT, we can include them in the next UKBBv2 array de-
sign and bloodTyper will report that discordant typing results have previously been observed
for samples carrying one of these variants. Furthermore, on the basis of these results research
samples will be taken from these donors upon their next donation to allow for further analysis
of altered antigen expression caused by these variants. Those new variants which can be
linked to an altered antigen phenotype will then be reported to the ISBT for inclusion in the
appropriate reference table.
While several targeted sequencing platforms have been reported previously, none of
them targets RBC, HPA and HNA antigens simultaneously.[105] Not only does our assay
provide excellent coverage of the genes underpinning these antigen systems, but it can also
sequence the most recently identified regulatory elements for these genes. Furthermore, no
previously published assays have included automated antigen interpretation software, instead,
past researches have relied upon manual inspection of sequencing alignments. This type of
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analysis is time-intensive and is unsuitable for use as a second-line test to investigate the one
percent of samples with discordant genotype-phenotype results (chapter 4) which are being
observed when applying the UKBB-v2 array.
During these experiments, we did not sequence any individuals for which antigen ex-
pression was underpinned by novel SVs, including complex ones. In other studies, we
have applied long-range sequencing to not only accurately identify individuals with the
U- phenotype, but also to characterise the exact break point location and nature of the
structural variation underlying this clinically important phenotype for patients of African
ancestry.[106] Knowledge of these breakpoints has now been encoded into the bloodTyper
algorithm enabling accurate antigen typing by assessing NGS read mapping statistics. In
future work, we plan to genotype/sequence DNA samples from blood donors with known
structural variants on the UKBBv2 array, the BGC capture assay, and the Oxford Nanopore
long-read sequencing platform allowing us to comprehensively validate and merge data from
all three technologies.
In summary, we have designed and validated the BGC capture NGS assay for resolving
samples with discordant results, a crucial tool for continued array development and valida-
tion as it allows for a high-resolution investigation of discordant typing results without the
requirement to seek fresh blood samples from donors. Currently, this test is more affordable
than analysis by WGS and has a significantly lower data footprint with alignments being on
average 522 Mb per BGC capture sample compared to 90 Gb per WGS sample. The BGC
platform also offers enhanced read coverage of antigen encoding genes in comparison to
commercially available WES assays. As the test is combined with automated interpretation
software it presents blood supply organisations with the ideal platform for routine investiga-
tion of patients with complex alloantibody profiles, blood cell antigens encoded by novel
gene haplotypes and for resolving genotype/phenotype discordances where antibody-based
phenotype is known. As outlined above an immense data richness that will be generated by
typing donors with historical extended typing data will rapidly result in a steep diminishment
of the number of discordances.
The BGC capture assay will also be an essential tool in ensuring the continued safe
integration of genotyping technologies such as the UKBBv2 array into clinical service where
it provides an accurate and affordable orthogonal method for confirmation of genotyping
results for antigens where only limited validation has previously been performed due to rarity
and lack of serological typing reagents or methods. Furthermore, as improved haplotype ref-
erence sequences become available for blood group encoding genes data from the previously
discordant sample can be re-analysed in light of new knowledge to improve antigen typing




As mentioned in the abstract of this thesis, the World Health Organisation reports that globally
118.5 million blood donations are collected each year.[107] This blood is used to provide
life-saving transfusion support for millions of individuals with a wide range of medical
conditions.
Blood transfusion is widely regarded as a safe procedure and this is due to the common
policy of identifying and ensuring compatibility between the ABO and RhD antigens of
donor and recipient for each transfusion. Although this policy prevents the majority of
adverse Haemolytic Transfusion Reactions, sensitisation to non-self RBC antigens remains
an unavoidable consequence of this matching strategy. The incidence of sensitisation after
a single transfusion episode has been approximated at 3%.[87, 88] In patients who require
chronic transfusion support, the incidence of immunisation can rise to 60%.[89–91, 63, 92]
Considering the vast scale of global blood transfusion, this means that each year at least one
million individuals will become sensitised as a direct result of the current ’one size fits all’
approach and 180,000 of the 300,000 infants born with an inherited haemoglobin disorder
will become sensitised due to the transfusion support they are dependant upon. This is of
course assuming that the standard of clinical care enjoyed in developed nations is applied
globally, which of course it is not.[107]
There is evidence to suggest that the frequency of immunisation events can be reduced
by increasing the level of matching between donor and recipient blood groups, and some
blood supply organisations have implemented this policy for patients who are most at risk of
immunisation events.[96, 108, 97] In order to implement such a policy for all transfusion
recipients, a large portion of donors needs to be typed for all clinically relevant red blood
cell (RBC) antigens. Many automated antibody- and DNA-based donor typing assays
have been developed, with studies reporting that 99.8% (5661/5672) of complex blood
requests could be served using just 43,066 donors genotyped for only a limited number of
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antigens.[94, 95, 36, 38] However, these tests are cost-prohibitive, do not type all clinically
relevant antigens and have thus not been adopted by global blood supply organisations. This
is exemplified by the fact that 85% of blood donors in England have no typing data clinically
relevant to RBC antigens such as those of the Duffy, Kidd, MNS, and Lutheran systems
and 94% of English donors in England have no typing data for rare antigens (information
from look-up in NHSBT’s PULSE database - 2019). Even though many advancements in
the donor typing field have been made, the lack of typed donors persists and broadly most
patients are still not benefiting from these developments.
In recent years the rapid fall in the cost of genome-wide DNA typing combined with
the development of advanced open-source bioinformatic analysis tools has brought about
the era of genomic precision medicine. Countries such as the UK have already successfully
integrated Whole Genome Sequencing (WGS) into routine clinical practice and the NHS
Executive have secured Illumina WGS capacity for 0.5 M DNA samples for the 2020-2023
period.[60]
The first studies investigating the use of WGS in Transfusion Medicine reported that the
technology could be used to better classify and type blood donors and patients, enabling us
to provide better-matched blood to patients that require regular transfusion, and to those who
are at risk of adverse antibody-related events.[66, 65] However, a deeper understanding of
the genetics underpinning blood group antigens that genomic data allowed was accompanied
by the lack of international standards on how to define the variation observed and how to link
it to antigen expression.
In chapter 3 of this thesis, we addressed these problems by conducting the first data-
driven review of blood group gene reference transcripts. This work resulted in the estab-
lishment of fixed Locus Reference Genomic records for each of the RBC antigen encoding
genes and has allowed the ISBT to link the antigen defining variants in their reference
tables to dbSNP identifiers and therefore coordinates in the human reference genome. We
demonstrated, by analysis of WGS data, how this international standard for interpretation of
blood group antigens from genetic data can be used to develop automated analysis tools such
as bloodTyper and to extract clinically relevant information from the genome sequencing
data of patients with rare diseases and cancer.
Although this represents an important step in introducing genomics-based matching of
blood, our analysis of genetic variation in the KEL locus of just 13,037 individuals resulted in
the discovery of 50-fold more unique haplotype sequences (n=1,697) than can be produced
by considering only the variation recorded in the ISBT reference tables (n=35). In order to
ensure the safe integration of genomics data into clinical practice, the transfusion medicine
community must take the next step and use high coverage WGS datasets such as those
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made available by the NIHR BioResource and the 100KGP to produce the fully phased
haplotype reference maps needed to improve the accuracy of genetically inferred antigen
types. Through continued international collaboration, we must ensure that this haplotype
reference resource covers all ethnicities.
We showed that WGS can produce highly accurate RBC and HPA antigen typing results
for patients, with 10,070 (99.5%) concordant results in 10,115 antigen typing results com-
parisons; however, WGS is currently too expensive to be applied to vast numbers of blood
donors. This leaves us in a similar situation as other tests; we have excellent typing data for
patients but have only limited typing data on the donors required to support them.
We address this dilemma in chapter 4 by reporting the development of the UKBBv2
genotyping array for donor genotyping. This affordable assay is capable of identifying almost
all clinically relevant RBC blood group antigens and also generated typing for HPA and
HLA antigens. We validated the test by genotyping 7,473 donors and observed 99·92%
concordance between clinical and array antigen typing results in 103,326 comparisons across
44 clinically relevant RBC, HLA and HPA antigens. Using the 1.2 million antigen genotyping
results produced we were able to achieve a 2.6-fold increase in the number of matches
identified in the same donors to support 3,146 historical complex patient cases with multiple
RBC alloantibodies. Demonstrating the immediate clinical value of the UKBBv2 array, the
data produced in this pre-clinical validation study was used to identify five compatible donors
for a Dutch patient with bone marrow failure requiring regular transfusions for whom no
compatible donors could be identified in the Netherlands.
To continue improving the design of the UKBBv2 donor genotyping array and ac-
companying bloodTyper interpretation software, it is essential to understand the cause of
discordances between genotype inferred- and antibody determined antigen types. To this
end, we developed the BGC capture assay, an affordable targeted NGS sequencing test that
can be deployed by blood supply organisations as a second-line test for investigation of
discordances observed between UKBBv2 array inferred and clinically recorded antigen types.
In chapter5 we used this assay to resolve 78% (57 / 73) of discordances between UKBBv2
array and donor record antigen types reported in chapter 4. In the remaining cases, we were
able to identify six previously unobserved DNA variants, which are likely to underpin altered
antigen phenotypes in 6 of the 16 discordant cases. For 10 discordances we were not able to
use the BGC sequencing assay due to lack of DNA for further analysis.
The fact that only 0.7% of donors used for validation in this study were of non-European
ancestry is a limiting factor of this work. Due to the low frequency of RH variant antigens
in Europeans and the high frequency in Sickle Cell patients of African ancestry, further
validation must be performed before this test can be used to clinically type these patients
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and the donors required to support them for variant antigens. Similarly, patients with
other haemoglobinopathies such as Thalassemia are frequently of Southern Mediterranean,
Persian, Arabian, and South-East Asian ancestry - populations in which blood group antigen
frequencies are also significantly different to those observed European ancestry individuals.
It is these patients who stand to benefit most from the extended matching that the technology
reported here enables, and it is, therefore, crucial to generate validation data on a large number
of individuals from these populations. The complete concordance between 835 antigen typing
results for the 57 non-European individuals and identification of two erroneous serological
typing results due to variant RhD antigen expression reported here, while not adequate for
validation purposes, provides support for further studies using samples from donors and
patients recruited by ancestry and specific antigen type.
In summary, the international standards, analysis software, donor genotyping assays, and
validation data presented in this thesis provides blood supply organisations with the opportu-
nity of implementing a policy of genomics-based precision transfusion medicine. Variants of
the UKBBv2 assay presented here will be used by the FinnGen Biobank, Million Veteran
Program, Taiwan Precision Medicine Initiative, and the impeding UK 5 Million studies. This
means that in the near future full blood cell antigen types will become available for millions
of patients and healthy individuals in the population. The transfusion medicine community
and global blood supply organisations should now take advantage of the developments in
clinical genomics by investing in the regulatory and computational infrastructure required to
make use of the dense antigen typing data which will become freely available. The BGC
collaboration of seven national blood supply organisations and the New York Blood Centre
will provide an exemplar of how genome-informed precision matching of blood and platelets
can be delivered at scale by obtaining regulatory approval for the UKBBv2 array typing test.
6.1 Translating this work
The immediate next step is to assess how accurately the UKBBv2 array can type the blood
group antigens of individuals of non-European ancestry. At the time of writing, the BGC
has already assembled a panel of 3,137 DNA samples from Dutch and American donors
of African ancestry and had these samples genotypes on the UKBBv2 array. Preliminary
comparisons have shown 99.73% concordance in 68,193 antigen typing comparisons, all
183 discordances concern antigens within the RH and MNS blood group systems which
are encoded by previously unobserved structural variation of the genome. On the basis of
these early results, the blood typing array content has been redesigned to incorporate probes
for accurate detection of structural variation in the relevant genes. In-depth analysis of this
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data, including serological confirmation of variant RH antigens, will be performed over the
coming months.
With the aim of integrating array genotyping technology into the global blood supply
chain, the BGC is now actively engaged in the process of seeking FDA regulatory approval of
a 50,000 variant, 384 sample format donor typing only Axiom array. In order to achieve this
on a global scale, the BGC has expanded its membership to now include the national blood
services of Australia, Canada, Finland, New Zealand, and South Africa and has planned a two-
phase accreditation study. In this study STRIDES NIHR BioResource samples from 60,000
NHSBT donors will be genotyped at NHSBT Colindale using Thermo Fisher’s GENETITAN-
MC instrument. In addition, samples from another 10,000 donors made available by the other
BGC members will be aggregated at NHSBT Cambridge. These 10,000 samples together
with 4,000 STRIDES samples will be genotyped at the clinical laboratories of NHSBT,
NYBC and Sanquin. Sample collection, DNA extraction and genotyping will be performed
in a clinically accredited setting. The data on 70,000 blood donors will be analysed in
Cambridge.
In Phase 1, the first 7,000 donor samples will be typed in a ’pre-clinical’ validation
exercise with the aim of further validate the genotyping platform itself alongside the processes
which have been put in place to bring genotyping into the blood service laboratories. The
results of this phase will also allow the BGC to take a final position for which antigens
approval will be sought from regulators for ‘diagnostic test status’ vs ‘screening test status’.
In Phase 2, the remaining 7,000, donor samples will be typed and the data will be used for
obtaining regulatory approval from the FDA and the European regulatory agencies. Sample
processing, genotyping, and data analysis will be performed in a ’hands off’ and regulated
manner - with antigen typing done ’on-board’ the GENETITAN instruments. Typing results,
antigen concordance data, and validation documentation will be presented to the regulatory
authorities.
In 2021 Thermo Fisher will also place a GENETITAN within the Australian Red Cross
Blood Service. It is expected that the four blood services with GENETITAN experience may
become ‘first clients’ if the array becomes accredited. In the UK the selection of the array
to be used for genotyping the 5M participants in the EDDRUK study will depend on the
outcome of a European tendering process.
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